Meggle Press Releases

MEGGLE brings latest lactose offerings to CPhI SEA in Bangkok


MEGGLE brings latest lactose offerings to CPhI SEA in Bangkok


Meggle150x88

Press Release | MEGGLE Excipients & Technology

MARCH 07, 2019

Wasserburg, Germany: – Pharmaceutical lactose specialist MEGGLE Wasserburg GmbH (MEGGLE) will use the upcoming CPhI South East Asia expo in Thailand later this month to present its expanded portfolio of lactose-based pharmaceutical excipients to the expanding Asian market.

MEGGLE Excipients & Technology has been a consistent presence at CPhI since the inaugural event in Jakarta in 2017. This time, it will be represented by its local partner Thai Meochems on stand D14 at the QSNCC expo center in Bangkok, with participation by a team from MEGGLE Singapore, led by Director Dr. Siang Meng Chua and Technical Application Manager, Dr. Chalermphon Wanawongthai.

Innovative lactose formulations

The MEGGLE display will feature a wide range of the company’s innovative lactose-based products and co-processed excipients including the ground-breaking Tablettose® agglomerated lactose, DuraLac® H anhydrous lactose and FlowLac® spray-dried alpha-lactose monohydrates, all of which have helped revolutionize direct compression (DC) tableting as well as the sieved, milled and micronized InhaLac® products for dry powder inhalation (DPI).

Video screens on the stand will provide visitors with insights into MEGGLE’s rigorous production standards, advanced technology and pioneering research work.

Total offer

“CPhI South East Asia provides the perfect platform to present the world-class MEGGLE product portfolio to the fast growing Asian pharma manufacturing sector as well as explore latest industry trends,” commented Dr. Siang Meng Chua.

“For this professional audience of manufacturers and product professionals, MEGGLE can provide a highly attractive total offer of leading edge excipients, formulation and regulatory support for solid dosage forms,” said Dr. Chua.

About MEGGLE Wasserburg

Bavarian-based MEGGLE Wasserburg is one of the world’s experts in lactose-based excipients and powder technology.

From its roots as a dairy operation in the late 1880s, MEGGLE has become one of the world’s leading manufacturers of pharmaceutical lactose, supplying the pharma market segment with a broad-based and unique lactose product portfolio.

MEGGLE Excipients & Technology has harnessed outstanding product quality and intelligent innovation to become a global leader in the manufacture of lactose-based excipients, focusing on products for direct tableting and dry powder inhalation.

A multidisciplinary team of committed and highly qualified people allows MEGGLE clients to benefit from pioneering experience and innovative drive in industrial milk and whey processing. The company constantly strives to develop high-tech, functional products for solid dosage form applications, where they can deliver maximum performance.

The company has introduced several pioneering products, notably Tablettose®, the world’s first agglomerated lactose for direct tableting, Cellactose® 80, a pioneering co-processed excipient based on cellulose-lactose for outstanding compression and flow properties and RetaLac®, the first direct compression co-processed excipient using a hypromellose-lactose base for modified sustained release and controlled release formulations.

About CPhI SEA 2019

CPhI South East Asia (SEA) is one of the most recent additions to UBM-organized franchise, extending the same multi-expo format that has made these pharma industry events so successful worldwide.

CPhI SEA caters to the ASEAN life sciences market, bundling six events under one roof with the CPhI pharma ingredients show co-located with P-MEC (machinery, technology and equipment), ICSE (contract manufacturing and services), InnoPack (packaging and drug delivery systems), LABworld (laboratory, analytical and biotech equipment) and the FDF show covering every aspect of the finished dosage supply chain.

CPhI SEA 2019 will be three-day event, opening March 12 at the Queen Sirkit National convention Center (QSNCC) in the Thai capital Bangkok. It is expected to attract some 5,500 attendees and exhibitors from more than 20 countries across the region as well as from Europe and North America.

The event is organized by UBM Live. More information at: https://www.cphi.com/sea/.

Media Contact

Margit Bonnetsmüller, Project Manager Marketing, MEGGLE Excipients & Technology Business Group
Tel: +49 8071 73 476
Email: Margit.Bonnetsmueller@meggle.de

Resources

Click on MEGGLE at CPhI SEA 2019 for more information.
Click on MEGGLE to contact the company directly.


Supplier Information
Supplier: MEGGLE Excipients & Technology
Address: Megglestrasse 6-12, 83512 Wasserburg, Germany
Tel: +49 8071 73-476
Fax: +49 8071 73-320
Website: https://www.meggle-pharma.com/


MEGGLE returns to DDL 2018 with new InhaLac® alpha-lactose excipient


MEGGLE returns to DDL 2018 with new InhaLac® alpha-lactose excipient


Meggle150x88

Press Release | MEGGLE Excipients & Technology

NOVEMBER 29, 2018

Wasserburg, Germany: – Pharmaceutical lactose specialist MEGGLE Excipients & Technology (MEGGLE) is returning as an exhibitor to the Drug Delivery to the Lungs (DDL) Conference in Edinburgh, showcasing its expanded range of lactose anhydrous and lactose monohydrate-based excipients.

MEGGLE, whose association with the DDL Conference extends back more than a decade, is a Silver Sponsor of the event.

Extended InhaLac® range

For the sixth year in succession, MEGGLE will be a DDL exhibitor with a stand at Booth 230 at the Edinburgh International Conference Center (EICC), from where it will display its extensive product portfolio for dry powder inhalation, featuring the InhaLac® range of sieved, milled and micronized inhalative lactose monohydrates.

The range is now extended by the addition of InhaLac® 160 as a sieved excipient ideal of nasal and pulmonary applications.

Sieved lactose for nasal and pulmonary applications

Developed at MEGGLE’s Wasserburg laboratories in Germany, InhaLac 160 is characterized by median particle size of approximately 110 μm, The new product fills a gap in the InhaLac range of coarse sieved lactose grades for dry powder inhalation, sitting between the coarser lactose InhaLac® 120 and the finer lactose InhaLac® 230.

This GMP/GDP certified sieved lactose is therefore suitable for pulmonary and nasal drug delivery and offers a range of benefits that include a dedicated production process, highly controlled powder characteristics, highest microbial quality including low endotoxins and retesting after 24 months.

Electrostatic charging insights

MEGGLE will submit a poster created with research partners RCPE on ‘Impact of relative humidity and powder filling level on the electrostatic charging behaviour of different capsule types’.

Two recent MEGGLE arrivals, Project Manager R&D Karin Hellauer and Project Manager DPI Dr. Lukas Neudert, will attend the DDL for the first time.

“We are looking forward to meeting the DDL community and to exchanging insights about pulmonary and nasal drug delivery,” said Ms. Hellauer.

“Once again, MEGGLE will provide significant input to the conference agenda, with our poster on electrostatic charging and with expert insights on optimum use of lactose excipients in dry powder granulation processes,” commented Dr. Neudert.

About MEGGLE Wasserburg

Bavarian-based MEGGLE Wasserburg is one of the world’s experts in lactose-based excipients and powder technology.

From its roots as a dairy operation in the late 1880s, MEGGLE has become one of the world’s leading manufacturers of pharmaceutical lactose, supplying the pharma market segment with a broad-based and unique lactose product portfolio.

MEGGLE Excipients & Technology has harnessed outstanding product quality and intelligent innovation to become a global leader in the manufacture of lactose-based excipients, focusing on products for direct tableting and dry powder inhalation.

A multidisciplinary team of committed and highly qualified people allows MEGGLE clients to benefit from pioneering experience and innovative drive in industrial milk and whey processing. The company constantly strives to develop high-tech, functional products for solid dosage form applications, where they can deliver maximum performance.

The company has introduced several pioneering products, notably Tablettose®, the world’s first agglomerated lactose for direct tableting, Cellactose® 80, a pioneering co-processed excipient based on cellulose-lactose for outstanding compression and flow properties and RetaLac®, the first direct compression co-processed excipient using a hypromellose-lactose base for modified sustained release and controlled release formulations.

About DDL 2018

The Drug Delivery to the Lungs (DDL) Conference (DDL) provides an annual forum for scientists, academics, clinicians, regulatory and industry specialists involved in developing medicines for inhalation.

DDL2018 is a three-day event opening December 12 at the Edinburgh International Conference Center (EICC) at The Exchange in the Scottish capital.

The 2018 conference will feature five themed sessions each with a combination of invited and submitted lectures given by experts in the field of inhalation and students working to advance respiratory science.

The event is organized by The Aerosol Society, with more information at: https://aerosol-soc.com/events/ddl2018/.

Media Contact

Margit Bonnetsmüller, Project Manager Marketing, MEGGLE Excipients & Technology Business Group
Tel: +49 8071 73 476
Email: Margit.Bonnetsmueller@meggle.de

Resources

Click on MEGGLE at DDL 2018 for more information.
Click on MEGGLE to contact the company directly.

MEGGLE Image 1a


Supplier Information
Supplier: MEGGLE Excipients & Technology
Address: Megglestrasse 6-12, 83512 Wasserburg, Germany
Tel: +49 8071 73-476
Fax: +49 8071 73-320
Website: https://www.meggle-pharma.com/


MEGGLE brings DPI insights and further InhaLac® innovation to RDD Asia


MEGGLE brings DPI insights and further InhaLac® innovation to RDD Asia


Meggle150x88

Press Release | MEGGLE Excipients & Technology

NOVEMBER 06, 2018

Wasserburg, Germany: – Pharmaceutical lactose experts MEGGLE Excipients & Technology (MEGGLE) will launch its latest dry powder inhalation grade product, InhaLac® 160, at the Asian Respiratory Drug Delivery, RDD 2018, in Kerala, India.

MEGGLE will also use RDD Asia to host a specialist interactive session on using purpose-formulated lactose grades in (DPI) formulations as part of the conference’s workshop track on Day Two of the event (November 15).

InhaLach® 160: pulmonary and nasal applications

The new InhaLac® 160 is characterized by a median particle size of approximately 110 μm, which ranges between the coarser lactose InhaLac® 120 and the finer lactose InhaLac® 230. This new excipient exhibits a narrowly distributed particle size with a fines content (particles below 15 μm) of only 3%.

This GMP/GDP certified sieved lactose is therefore suitable for pulmonary and nasal drug delivery and offers a range of benefits that include a dedicated production process, highly controlled powder characteristics, highest microbial quality including low endotoxins and retesting after 24 months.

“This new InhaLac product rounds out our inhalative grade lactose portfolio, closing the narrow gap that existed in our range of coarse sieved lactose grades for dry powder inhalation,” commented MEGGLE Head of Marketing, Christoph Adler.

DPI Formulations workshop

The MEGGLE workshop ‘Get the Right Grade- An Inhalative Lactose Guide for DPI Formulations’ will use case studies and a live demonstration to explain how the particle size of the carrier significantly changes the delivered dose and fine particle fraction of DPIs.

It will provide insights into the complex relationships between carrier lactose properties and delivery device characteristics to reveal what type of carrier is most suitable for which type of device. The case studies will also explore how lactose fines are often used in conjunction with carrier lactose (ternary powder formulations) to optimize DPI performance.

The one hour workshop will include a demonstration and questions, designed for up to 40 RDD delegates to explore detailed issues and encourage audience interaction and will be repeated three times during the conference.

Sharing knowledge worldwide

“By attending this session participants will gain a deeper understanding of what lactose carrier and fines can achieve in a DPI formulation,” commented Mr. Adler.

MEGGLE does much work to promote best practice and knowledge sharing in the dry inhalation community worldwide and share its world-leading technical expertise on co-processed lactose, anhydrous and lactose monohydrate-based excipients.

It recently joined leading sponsors, instigators and participants to host the ‘Inhalation Insights’ series of symposiums touring the Eastern United States. The events provided discussion and new perspectives on latest DPI technologies and processes, targeted at researchers and technicians working in the sector.

MEGGLE is proud to be part of this “Inhalation Insights” expert group.

About MEGGLE Wasserburg

Bavarian-based MEGGLE Wasserburg is one of the world’s experts in lactose-based excipients and powder technology.

From its roots as a dairy operation in the late 1880s, MEGGLE has become one of the world’s leading manufacturers of pharmaceutical lactose, supplying the pharma market segment with a broad-based and unique lactose product portfolio.

MEGGLE Excipients & Technology has harnessed outstanding product quality and intelligent innovation to become a global leader in the manufacture of lactose-based excipients, focusing on products for direct tableting and dry powder inhalation.

A multidisciplinary team of committed and highly qualified people allows MEGGLE clients to benefit from pioneering experience and innovative drive in industrial milk and whey processing. The company constantly strives to develop high-tech, functional products for solid dosage form applications, where they can deliver maximum performance.

The company has introduced several pioneering products, notably Tablettose®, the world’s first agglomerated lactose for direct tableting, Cellactose® 80, a pioneering co-processed excipient based on cellulose-lactose for outstanding compression and flow properties and RetaLac®, the first direct compression co-processed excipient using a hypromellose-lactose base for modified sustained release and controlled release formulations.

About RDD Asia 2018

The 2018 Asian Respiratory Drug Delivery Conference (RDD Asia 2018) is a three day event opening November 14 at the Grand Hyatt Kochi in Kerala, India.

The conference will cover a wide range of respiratory drug solutions and technologies, with sessions focusing on Advancing Regulatory Science of Inhaled and Nasal Products, Predictive Models to Support Inhalation Science and Satisfying Patient Needs in the Global Marketplace.

A further session will include a range of interactive workshops hosted by leading providers.

The conference will be opened by Professor Richard N. Dalby of the University of Maryland’s School of Pharmacy and the plenary lecture on ‘Challenging the Bioequivalence Hurdles for OINDPs: Achieving Q3 Structural Equivalence’ will be delivered by Dr. Robert Price, from the , Department of Pharmacy and Pharmacology at the UK’s University of Bath.

The conference will also feature a scientific poster session and co-located Technology Exhibition and will conclude with a Gala Dinner.

The event is organized by RDD Online with further information at:
https://www.rddonline.com/rdd/rdd.php?id=16&sid=1.

Media Contact

Margit Bonnetsmüller, Project Manager Marketing, MEGGLE Excipients & Technology Business Group
Tel: +49 8071 73 476
Email: Margit.Bonnetsmueller@meggle.de

Resources

Click on MEGGLE launches InhaLac® 160 at RDD Asia for more information.
Click on MEGGLE to contact the company directly.

MEGGLE Image 1

MEGGLE Image 2


Supplier Information
Supplier: MEGGLE Excipients & Technology
Address: Megglestrasse 6-12, 83512 Wasserburg, Germany
Tel: +49 8071 73-476
Fax: +49 8071 73-320
Website: https://www.meggle-pharma.com/


MEGGLE helps make wishes come true at Environment & Health Day


MEGGLE helps make wishes come true at Environment & Health Day


Meggle150x88

Press Release | MEGGLE Excipients & Technology

OCTOBER 18, 2018

Wasserburg, Germany: – MEGGLE has provided hundreds of its people with healthy offers as well as helping to meet the wishes of children in need at its recent Environment & Health Day.

At the MEGGLE dairy’s Environment and Health Day, workers had the chance to spend some of their working hours putting their bodies to the test. More than 250 staffers took up the huge range of health options on offer, ranging from mobility check-ups or nutrition advice to cardiac stress tests. By taking part, the staff were also supporting a good cause; this year the newly introduced Wasserburger Wunschbaum (“Wasserburg Make a Wish Tree”).

Wish tree

Proceeds from a cake sale and basketball contest were donated to the Wish Tree Association, rounded up to €2.000 by MEGGLE management. The Association has been encouraging children from socially disadvantaged families to write down their most fervent hope and hang it from the tree. Wishes included a new schoolbag, a trip to a wildlife park with their parents and a snazzy sports shirt.

“Some of the requests may be for very small things, but they are things that would bring those children such joy,” commented Thomas Ranft, the company’s Health & Safety and Environmental Management Officer.

Big response

Mr. Ranft organised the event in the canteen courtyard at the Wasserburg dairy together with his team, which once again this year included a number of apprentices. External partners AOK, Barmer, Techniker Krankenkasse and Optik Götz lent the Day their support.

The team were delighted with the response.

“Of course, it is ultimately up to each individual to look after their own health. But employers can raise awareness of this topic amongst their employees on a regular basis. MEGGLE does this continuously throughout the year and this is already the eleventh time we have held our big Environment and Health Day”, said Mr. Ranft.

“Being able to have several tests done in quick succession and having lots of experts all together in the same place are hugely beneficial, as normally appointments with specialists are typically difficult to get and have to be made a long time in advance. But our people were able to take advantage of the health checks on offer during their working hours,” he added.

Environmental issues

Issues relating to the environment and sustainability were also on the agenda, with working groups using wall displays to inform colleagues about scope to make energy and resource savings in their everyday routines.

“Our environmental officers also appealed to everyone to continue using our resources sparingly and with an eye on the future,” said Thomas Ranft.

About MEGGLE Wasserburg

Bavarian-based MEGGLE Wasserburg is one of the world’s experts in lactose based excipients and powder technology.

From its roots as a dairy operation in the late 1880s, MEGGLE has become one of the world’s leading manufacturers of pharmaceutical lactose, supplying the pharma market segment with a broad-based and unique lactose product portfolio.

MEGGLE Excipients & Technology has harnessed outstanding product quality and intelligent innovation to become a global leader in the manufacture of lactose-based excipients, focusing on products for direct tableting and dry powder inhalation.

A multidisciplinary team of committed and highly qualified people allows MEGGLE clients to benefit from pioneering experience and innovative drive in industrial milk and whey processing. The company constantly strives to develop high-tech, functional products for solid dosage form applications, where they can deliver maximum performance.

The company has introduced several pioneering products, notably Tablettose®, the world’s first agglomerated lactose for direct tableting, Cellactose® 80, a pioneering co-processed excipient based on cellulose-lactose for outstanding compression and flow properties and RetaLac®, the first direct compression co-processed excipient using a hypromellose-lactose base for modified sustained release and controlled release formulations.

Media Contact

Margit Bonnetsmüller, Project Manager Marketing, MEGGLE Excipients & Technology Business Group
Tel: +49 8071 73 476
Email: Margit.Bonnetsmueller@meggle.de

Resources

Click on MEGGLE Environment and Health Day for more information.
Click on MEGGLE to contact the company directly.

More than 250 employees took up the great health chances on offer during MEGGLE Environment & Health Day

More than 250 employees took up the great health chances on offer during MEGGLE Environment & Health Day


Supplier Information
Supplier: MEGGLE Excipients & Technology
Address: Megglestrasse 6-12, 83512 Wasserburg, Germany
Tel: +49 8071 73-476
Fax: +49 8071 73-320
Website: https://www.meggle-pharma.com/


MEGGLE returns to leading LatAm Congress


MEGGLE returns to leading LatAm Congress


Meggle150x88

Press Release | MEGGLE Excipients & Technology

OCTOBER 05, 2018

Wasserburg, Germany: – Pharmaceutical lactose specialist MEGGLE Excipients & Technology (MEGGLE) will show its advanced range of lactose-based excipients and ingredients for granulation and direct compression at the 10th Congress and Exhibition For Pharmaceutical, Biotechnological, Veterinarian And Cosmetics Science And Technology (ETIF 2018) in the Argentinian capital; Buenos Aires.

MEGGLE is returning to the event following previous attendances and will once again exhibit in partnership with its Argentine distributor, Etilfarma S.A.

Co-processed excipients

From its stand at Booth 429 at the Centro Costa Salguero, MEGGLE will showcase a selected range of lactose anhydrous and lactose monohydrate-based pharmaceutical grade excipients as well as expert knowledge on how ingredients should be applied, combined and stored.

In particular, the MEGGLE display will include leading edge co-processed lactose-based excipients like Cellactose®80, MicroceLac®100, StarLac®, RetaLac® and CombiLac® that support a wide range of direct compression (DC) and dry granulation (DG) applications, along with micronized InhaLac® for dry powder inhalation (DPI) formulations.

User benefits

“We are using ETIF 2018 to address an important audience representing key R&D, pharmacotechnical, purchase and production sectors of the pharma industry in Argentina and South America,” noted Fábio Luis Ikuno, Managing Director of MEGGLE Latin America, “These are decision makers who value shorter development times, greater efficiency, cost benefits and quality, all of which MEGGLE can deliver,” added Mr. Fábio Luis Ikuno.

About MEGGLE Wasserburg

Bavarian-based MEGGLE Wasserburg is one of the world’s experts in lactose-based excipients and powder technology.

From its roots as a dairy operation in the late 1880s, MEGGLE has become one of the world’s leading manufacturers of pharmaceutical lactose, supplying the pharma market segment with a broad-based and unique lactose product portfolio.

MEGGLE Excipients & Technology has harnessed outstanding product quality and intelligent innovation to become a global leader in the manufacture of lactose-based excipients, focusing on products for direct tableting and dry powder inhalation.

A multidisciplinary team of committed and highly qualified people allows MEGGLE clients to benefit from pioneering experience and innovative drive in industrial milk and whey processing. The company constantly strives to develop high-tech, functional products for solid dosage form applications, where they can deliver maximum performance.

The company has introduced several pioneering products, notably Tablettose®, the world’s first agglomerated lactose for direct tableting, Cellactose®80, a pioneering co-processed excipient based on cellulose-lactose for outstanding compression and flow properties and RetaLac®, the first direct compression co-processed excipient using a hypromellose-lactose base for modified sustained release and controlled release formulations.

About ETIF 2018

Argentina’s Congress and Exhibition for Pharmaceutical, Biotechnological, Veterinarian and Cosmetics Science and Technology (ETIF) is one of most influential events for the Pharmaceutical Industry in South America.

The 10th Congress, ETIF 2018, is a three day event opening October 16 at the Centro Costa Salguero in Buenos Aires, providing a forum for leaders of the pharmaceutical, biotech, veterinary and cosmetics Industries to see and exhibit the latest technological innovations, the most advanced products and services and new developments within a permanently developing sector.

ETIF will also offer four conference strands of specialized discussion in the Scientific-Technical Congress.

The event is organized by ETIF with further information available at: http://www.etif.com.ar/index_en.php.

Media Contact

Margit Bonnetsmüller, Project Manager Marketing, MEGGLE Excipients & Technology Business Group
Tel: +49 8071 73 476
Email: Margit.Bonnetsmueller@meggle.de

OR

Fábio Luis Ikuno, Managing Director, MEGGLE Latin America
Tel: +55 11 2893 4831
Mob: +55 11 99152 0657
Email: fabio.ikuno@meggle.com

OR

Guilherme Sandoval Brandão, Application Technology Coordinator, MEGGLE Latin America
Tel: +55 11 2893 4822
Mob: +55 11 9630 58939
Email: guilherme.brandao@meggle.com

Resources

Click on MEGGLE at ETIF 2018 for more information.
Click on MEGGLE to contact the company directly.


Supplier Information
Supplier: MEGGLE Excipients & Technology
Address: Megglestrasse 6-12, 83512 Wasserburg, Germany
Tel: +49 8071 73-476
Fax: +49 8071 73-320
Website: https://www.meggle-pharma.com/


MEGGLE brings green values to CPhI Worldwide


MEGGLE brings green values to CPhI Worldwide


Meggle150x88

Press Release | MEGGLE Excipients & Technology

SEPTEMBER 28, 2018

Wasserburg, Germany: – Pharmaceutical lactose specialist MEGGLE Excipients & Technology (MEGGLE) will once again be a distinctive presence at the huge CPhI Worldwide expo in Madrid with its huge range of lactose-based pharmaceutical excipients.

MEGGLE is one of CPhI’s most established exhibitors, having attended every worldwide expo for more than 20 years, almost since the event was initially founded in 1991.

Consistent presence

“MEGGLE has been a consistent annual presence at CPhI Worldwide for more than two decades. This is one of our favorite networking platforms to meet our important business partners, present our product portfolio and exchange knowledge and insights with pharmaceutical industry experts,” said Christoph Adler, Head of Marketing, who will be a prominent member of the MEGGLE team in Madrid.

Mr. Adler will be a member of the team on the MEGGLE stand at Booth 8C91, as part of the Excipients Zone in Hall 8 of the IFEMA Center in Madrid.

Combining tradition with innovation

Once again, MEGGLE’s stand will be instantly recognizable for its ‘green moss’ look. As with the previous stand at CPhI 2017 in Frankfurt, the stand will combine a showcase of the company’s product portfolio and a gallery of its 148-year history with a comfortable reception area for face-to-face meetings.

“As our customers have come to expect, our stand will offer a family atmosphere, latest news about MEGGLE, advice on our products from experts in Sales, Application Technology and R&D, excellent catering and the latest edition of our famous MEGGLE cow!” he added.

MEGGLE has retained the “moss covered” visual theme for its stand that proved popular at previous CPhI expos but with a new twist to be revealed in Madrid.

“The moss theme encapsulates MEGGLE’s core values of sustainability, traditions and innovation,” said Mr. Adler.

MEGGLE is currently accepting bookings for meetings during CPhI Worldwide.

The MEGGLE range of sophisticated lactose-based ingredients and excipients, including Lactose Monohydrate, Lactose Anhydrous, Co-processed Lactose and Lactose for Dry Powder Inhalation (sieved, milled and micronized) support dry and wet granulation, capsules filling, direct compression and DPI applications.

About MEGGLE Wasserburg

Bavarian-based MEGGLE Wasserburg is one of the world’s experts in lactose based excipients and powder technology.

From its roots as a dairy operation in the late 1880s, MEGGLE has become one of the world’s leading manufacturers of pharmaceutical lactose, supplying the pharma market segment with a broad-based and unique lactose product portfolio.

MEGGLE Excipients & Technology has harnessed outstanding product quality and intelligent innovation to become a global leader in the manufacture of lactose-based excipients, focusing on products for direct tableting and dry powder inhalation.

A multidisciplinary team of committed and highly qualified people allows MEGGLE clients to benefit from pioneering experience and innovative drive in industrial milk and whey processing. The company constantly strives to develop high-tech, functional products for solid dosage form applications, where they can deliver maximum performance.

The company has introduced several pioneering products, notably Tablettose®, the world’s first agglomerated lactose for direct tableting, Cellactose® 80, a pioneering co-processed excipient based on cellulose-lactose for outstanding compression and flow properties and RetaLac®, the first direct compression co-processed excipient using a hypromellose-lactose base for modified sustained release and controlled release formulations.

About CPhI Worldwide 2018

CPhI Worldwide is the flagship annual trade show for pharma ingredients and partner sourcing providing delegates and exhibitors opportunities to arrange face-to-face meetings with potential international pharmaceutical partners and collaborators and gain insights on latest industry trends.

Now in its 29th year, the 2018 event is a three-day event opening October 9 at IFEMA, Feria de Madrid, Spain, which last hosted the event in 2015. CPhI Worldwide 2018. CPhI Worldwide includes the co-located zoned exhibitions; ICSE Outsourcing solutions, P-MEC Machinery and Equipment and InnoPack pharmaceutical packaging events. Together, they are expected to attract a record 45,000 delegates along with 2,500 exhibiting companies from 153 countries.

New for 2018, the Expo will feature bioLIVE, a new specialized exhibition focusing on the biopharmaceutical industry.

The CPhI series is staged by leading Global B2B Events Organizer and Publisher UBM Live More information at: https://www.cphi.com/europe/.

Media Contact

Margit Bonnetsmüller, Project Manager Marketing, MEGGLE Excipients & Technology Business Group
Tel: +49 8071 73 476
Email: Margit.Bonnetsmueller@meggle.de

Resources

Click on MEGGLE at CPhI Worldwide 2018 for more information.
Click on MEGGLE to contact the company directly.

Mossy look: MEGGLE’s stand at CPhI Worldwide 2017 in Frankfurt

Mossy look: MEGGLE’s stand at CPhI Worldwide 2017 in Frankfurt

MEGGLE’s CPhI stand will feature a historical gallery of people and events from the past 148 years

MEGGLE’s CPhI stand will feature a historical gallery of people and events from the past 148 years

The MEGGLE brand has been represented at every CPhI Worldwide for more than 20 years

The MEGGLE brand has been represented at every CPhI Worldwide for more than 20 years


Supplier Information
Supplier: MEGGLE Excipients & Technology
Address: Megglestrasse 6-12, 83512 Wasserburg, Germany
Tel: +49 8071 73-476
Fax: +49 8071 73-320
Website: https://www.meggle-pharma.com/


MEGGLE co-sponsors Inhalation Insights symposium series


MEGGLE co-sponsors Inhalation Insights symposium series


Meggle150x88

Press Release | MEGGLE Excipients & Technology

SEPTEMBER 17, 2018

Wasserburg, Germany: – Pharmaceutical lactose specialist MEGGLE Excipients & Technology (MEGGLE) is among the leading sponsors, instigators and participants in the Inhalation Insights series of symposiums that will soon be touring the Eastern seaboard of the USA.

Inhalation Insight event is a Dry Powder Inhalation Technology Symposium that provides discussion and new perspectives on latest technologies and processes, targeted at researchers and technicians working in the DPI arena.

Lactose based co-processed excipients

MEGGLE will bring to the events its technical expertise on lactose monohydrate-based inhalation grade excipients that are vital components in dry powder inhalation products and manufacturing processes.

Head of Research & Development at MEGGLE, Dr. Mirjam Kobler, will start each event with a presentation on the key roles of “Lactose in dry powder inhaler formulations”.

Co-operative series

The first symposium will be held in New Jersey on September 25, followed within three days by further workshops in North Carolina and Florida.
MEGGLE is joined by Harro Höfliger, CSP Technologies and Experic in contributing content and experts to the series.

About MEGGLE Wasserburg

Bavarian-based MEGGLE Wasserburg is one of the world’s experts in lactose based excipients and powder technology.

From its roots as a dairy operation in the late 1880s, MEGGLE has become one of the world’s leading manufacturers of pharmaceutical lactose, supplying the pharma market segment with a broad-based and unique lactose product portfolio.

MEGGLE Excipients & Technology has harnessed outstanding product quality and intelligent innovation to become a global leader in the manufacture of lactose-based excipients, focusing on products for direct tableting and dry powder inhalation.

A multidisciplinary team of committed and highly qualified people allows MEGGLE clients to benefit from pioneering experience and innovative drive in industrial milk and whey processing. The company constantly strives to develop high-tech, functional products for solid dosage form applications, where they can deliver maximum performance.

The company has introduced several pioneering products, notably Tablettose®, the world’s first agglomerated lactose for direct tableting, Cellactose® 80, a pioneering co-processed excipient based on cellulose-lactose for outstanding compression and flow properties and RetaLac®, the first direct compression co-processed excipient using a hypromellose-lactose base for modified sustained release and controlled release formulations.

About Inhalation Insights 2018

Inhalation Insights is the brand name for the Dry Powder Inhalation (Symposium, an annual roadshow type forum serving centers on the East Coast of the USA. The program at each event is focused on sharing first-hand knowledge related to dry powder inhalation (DPI) technology, taking in the complete process chain from powder characteristics and formulations to assembly, packaging and testing.

The symposium promotes discussions on the latest market trends and insights into the latest state of the art regarding devices, clinical testing, excipients and manufacturing technology.

The one day symposia are being held on successive days starting September 25 at Basking Ridge, New Jersey, followed by Durham, North Carolina the next day and on September 28 at Fort Lauderdale, Florida.

The program is organized by Inhalation Insights, which is a joint organisation supported by Harro Höfliger, CSP Technologies, Experic and MEGGLE. Further information at: https://usa.inhalation-insights.com.

Media Contact

Margit Bonnetsmüller, Project Manager Marketing, MEGGLE Excipients & Technology Business Group
Tel: +49 8071 73 476
Email: Margit.Bonnetsmueller@meggle.de

Resources

Click on MEGGLE sponsoring Inhalation Insights for more information.
Click on MEGGLE to contact the company directly.
Click on Inhalation Insights to book a place at symposium.


Supplier Information
Supplier: MEGGLE Excipients & Technology
Address: Megglestrasse 6-12, 83512 Wasserburg, Germany
Tel: +49 8071 73-476
Fax: +49 8071 73-320
Website: https://www.meggle-pharma.com/


MEGGLE heads to Colombia for Farmacosmética conference


MEGGLE heads to Colombia for Farmacosmética conference


Meggle150x88

Press Release | MEGGLE Excipients & Technology

SEPTEMBER 11, 2018

Wasserburg, Germany: – Pharmaceutical lactose specialist MEGGLE Excipients & Technology (MEGGLE) is returning as an exhibitor to the influential Farmacosmética 2018 in Medellin, Colombia.

MEGGLE will bring to the event a selected range of lactose anhydrous and lactose monohydrate-based pharmaceutical grade excipients that are vital components in processes across the pharmaceutical and cosmetics industries.

Lactose based co-processed excipients

In partnership with its exclusive Colombian distributor, Händler S.A.S., MEGGLE will be exhibiting at booths 135 and 136 at the Medellin Expo Center.

The MEGGLE display will cover a huge range of advanced lactose-based ingredients and excipients with particular emphasis on lactose based co-processed excipients Cellactose®80, MicroceLac®100, StarLac®, CombiLac® and RetaLac®, a ground-breaking hypromellose-lactose base for enhanced controlled release in oral dispersible tablet (ODT) and oral sustained release formulations.

Value-added offers

MEGGLE will also present its range of value-added technical consultancy and troubleshooting services.

Managing Director of MEGGLE Latin America, Fábio Luis Ikuno, will be a prominent presence on the stand.

This is a key platform from which to reach out to the research and development, pharmacotechnical, purchasing and production communities within the pharma industry in Colombia and across Latin America,” commented Mr. Ikuno.

“We will be using the opportunity to show how we can offer them reduced development times, greater efficiency, enhanced quality and cost benefits,” said Mr. Ikuno.

About MEGGLE Wasserburg

Bavarian-based MEGGLE Wasserburg is one of the world’s experts in lactose based excipients and powder technology.

From its roots as a dairy operation in the late 1880s, MEGGLE has become one of the world’s leading manufacturers of pharmaceutical lactose, supplying the pharma market segment with a broad-based and unique lactose product portfolio.

MEGGLE Excipients & Technology has harnessed outstanding product quality and intelligent innovation to become a global leader in the manufacture of lactose-based excipients, focusing on products for direct tableting and dry powder inhalation.

A multidisciplinary team of committed and highly qualified people allows MEGGLE clients to benefit from pioneering experience and innovative drive in industrial milk and whey processing. The company constantly strives to develop high-tech, functional products for solid dosage form applications, where they can deliver maximum performance.

The company has introduced several pioneering products, notably Tablettose®, the world’s first agglomerated lactose for direct tableting, Cellactose® 80, a pioneering co-processed excipient based on cellulose-lactose for outstanding compression and flow properties and RetaLac®, the first direct compression co-processed excipient using a hypromellose-lactose base for modified sustained release and controlled release formulations.

About Farmacosmética 2018

The annual Farmacosmética conference provides a platform for sharing academic and commercial knowledge across the pharmaceutical and cosmetic industries. The event is one of the most important pharma events in Latin America.

It currently attracts around 1,000 attendees, representing professionals from all levels and areas of the pharma and cosmetic industries.

Farmacosmética 2018 is a three-day event opening September 20 at the Medellin Congress Center and will feature three related conferences: The XV Colombian Symposium on Cosmetic Science and Technology, the XI Congress of Pharmaceutical Sciences and the XX Congress of the South American Pharmaceutical Federation. Alongside the academic symposium and congresses, there is a co-located trade exhibition.

Farmacosmética 2018 is organized by the National College of Pharmaceutical Chemists of Colombia and the Colombian Association of Cosmetic Science and Technology with further information at: http://farmacosmetica.com.co/.

Media Contact

Fábio Luis Ikuno, Managing Director, MEGGLE Latin America
Phone: +55 11 2893 4831
Mobile: +55 11 99152 0657
Email: fabio.ikuno@meggle.com

OR

Margit Bonnetsmüller, Project Manager Marketing, MEGGLE Excipients & Technology Business Group
Tel: +49 8071 73 476
Email: Margit.Bonnetsmueller@meggle.de

Resources

Click on MEGGLE at Farmacosmética Colombia 2018 for more information.
Click on MEGGLE to contact the company directly.


Supplier Information
Supplier: MEGGLE Excipients & Technology
Address: Megglestrasse 6-12, 83512 Wasserburg, Germany
Tel: +49 8071 73-476
Fax: +49 8071 73-320
Website: https://www.meggle-pharma.com/


MEGGLE makes debut at Maghreb Pharma, Algiers


MEGGLE makes debut at Maghreb Pharma, Algiers


Meggle150x88

Press Release | MEGGLE Excipients & Technology

AUGUST 31, 2018

Wasserburg, Germany: – Pharmaceutical lactose specialist MEGGLE Excipients & Technology (MEGGLE) is underlining its presence in the fast expanding MENA pharma manufacturing market with a presence at September’s Maghreb Pharma Expo in Algiers.

This will be MEGGLE’s first attendance at this recently founded and rapidly growing event, now recognized as one of Africa’s leading pharma-tech B2B platforms.

Wide lactose range

MEGGLE will share Stand A2 at the SAFEX exhibition center in Algiers with its regional distribution partner, UNIPEX Solutions.

The MEGGLE display will emphasize direct compressible lactose types like Tablettose, FlowLac, DuraLac and its wide range of co-processed excipients.

“We will be able to show that our product portfolio of lactose based excipients covers all relevant applications: direct compression, wet- and dry granulation, powder preparations for capsule and sachet filling and dry powder inhalation,” said Christoph Adler, MEGGLE Head of Marketing & Area Manager.

Leading-edge excipients

“This event provides us with a great opportunity to share information and knowledge about leading edge excipients and their place in the latest manufacturing methods,” he added.

Dr. Franz-Karl Penz, MEGGLE Head of Application Management, will be on stand in Algiers to answer technical and detailed questions, along with MEGGLE Area Manager for the Africa Region, Dr. Karim Maarif.

“We are very much looking forward to the Algiers event,” commented Dr. Karim Maarif.

“As the biggest exhibition in North Africa, Maghreb Pharma presents a perfect opportunity to meet our existing customers and to present our product portfolio to our core audience of purchasing and R&D decision-makers,” said Dr. Maarif.

Nearby, on Stand F8, MEGGLE will also be represented by its Tunisian distribution partner, Pharma Labo.

About MEGGLE Wasserburg

Bavarian-based MEGGLE Wasserburg is one of the world’s experts in lactose based excipients and powder technology.

From its roots as a dairy operation in the late 1880s, MEGGLE has become one of the world’s leading manufacturers of pharmaceutical lactose, supplying the pharma market segment with a broad-based and unique lactose product portfolio.

MEGGLE Excipients & Technology has harnessed outstanding product quality and intelligent innovation to become a global leader in the manufacture of lactose-based excipients, focusing on products for direct tableting and dry powder inhalation.

A multidisciplinary team of committed and highly qualified people allows MEGGLE clients to benefit from pioneering experience and innovative drive in industrial milk and whey processing. The company constantly strives to develop high-tech, functional products for solid dosage form applications, where they can deliver maximum performance.

The company has introduced several pioneering products, notably Tablettose®, the world’s first agglomerated lactose for direct tableting, Cellactose® 80, a pioneering co-processed excipient based on cellulose-lactose for outstanding compression and flow properties and RetaLac®, the first direct compression co-processed excipient using a hypromellose-lactose base for modified sustained release and controlled release formulations.

About Maghreb Pharma 2018

The Maghreb Pharma Expo bills itself as Africa’s largest pharma-tech B2B platform hosting more than 2,200 visiting pharma professionals and close to 200 exhibitors from 28 countries.

Maghreb Pharma 2018 is a three day event opening September 17 at the SAFEX exhibition center in Algiers, Algeria.

The networking and knowledge-sharing event features more than 40 free industry seminars, covering the whole spectrum of pharmaceutical manufacturing and ingredients sourcing.

The co-located exhibition features suppliers, products and services that cover the entire supply chain for local pharmaceutical manufacturers.

The event is organized by Easyfairs Northeral, with further information at: https://www.easyfairs.com/maghreb-pharma-2018/maghreb-pharma-2018/.

Media Contact

Margit Bonnetsmüller, Project Manager Marketing, MEGGLE Excipients & Technology Business Group
Tel: +49 8071 73 476
Email: Margit.Bonnetsmueller@meggle.de

Resources

Click on MEGGLE at Maghreb Pharma 2018 for more information.
Click on MEGGLE to contact the company directly.
Click on UNIPEX at Maghreb for stand information.


Supplier Information
Supplier: MEGGLE Excipients & Technology
Address: Megglestrasse 6-12, 83512 Wasserburg, Germany
Tel: +49 8071 73-476
Fax: +49 8071 73-320
Website: https://www.meggle-pharma.com/


MEGGLE returns to CPhI China in Shanghai


MEGGLE returns to CPhI China in Shanghai


Meggle150x88

Press Release | MEGGLE Excipients & Technology

JUNE 05, 2018

Wasserburg, Germany: – Pharmaceutical lactose specialist MEGGLE Excipients &Technology (MEGGLE) will return as an exhibitor to the huge CPhI China expo in Shanghai to showcase its innovative range of lactose-based pharmaceutical excipients to it’s expanding Asian markets.

MEGGLE will again be exhibiting at Booth W5B02 at Shanghai’s huge SNIEC Center.

“Once again, this great event gives us a fabulous platform from which to bring MEGGLE’s brand values and our leading role in the pharmaceutical industry to a Chinese and South East Asian audience,” commented MEGGLE.

Director Rep. Office Shanghai, Dr. Yi Kang, who will lead the MEGGLE presence at CPhI China.

Lactose products and excipients

Dr. Kang will be assisted by Sophia Yao, technical manager and Fisher Yu in showcasing a wide range of their lactose-based products and co-processed excipients.

These will include milled lactose grades like GranuLac® 70, GranuLac 140, GranuLac 200, GranuLac 230, SorbLac® 400, as well as sieved lactose (PrismaLac® 40, CapsuLac® 60, SacheLac® 80, SpheroLac® 100), direct compression lactose and agglomerated lactose (Tablettose® 70, Tablettose 80, Tablettose 100).

MEGGLE will also display spray-dried lactose (FlowLac® 90, FlowLac 100) anhydrous DuraLac® and co-processed excipients such as Cellactose® 80, MicroceLac® 100, CombiLac® and RetaLac®.

Inhalation grade

It will also feature its inhalation grade lactoses such as sieved InhaLac® 70, InhaLac ® 120,InhaLac® 230, InhaLac® 251, along with milled InhaLac® 400, the recently developed micronized InhaLac® 500 and Lactose Monohydrate Low Endotoxin.

Web-based configuration

MEGGLE will also use its stand display to introduce end-users to the Chinese language version of its recently developed Product Configurator on its website that allows customers to identify the correct product by basic applications and characteristics. (See link below).

“We will be able to show that MEGGLE is an important partner for many manufacturers in the rapidly expanding and increasingly sophisticated Chinese market,” said Sophia Yao.

About MEGGLE Wasserburg

Bavarian-based MEGGLE Wasserburg is one of the world’s experts in lactose based excipients and powder technology.

From its roots as a dairy operation in the late 1880s, MEGGLE has become one of the world’s leading manufacturers of pharmaceutical lactose, supplying the pharma market segment with a broad-based and unique lactose product portfolio.

MEGGLE Excipients & Technology has harnessed outstanding product quality and intelligent innovation to become a global leader in the manufacture of lactose-based excipients, focusing on products for direct tableting and dry powder inhalation.

A multidisciplinary team of committed and highly qualified people allows MEGGLE clients to benefit from pioneering experience and innovative drive in industrial milk and whey processing. The company constantly strives to develop high-tech, functional products for solid dosage form applications, where they can deliver maximum performance.

The company has introduced several pioneering products, notably Tablettose®, the world’s first agglomerated lactose for direct tableting, Cellactose® 80, a pioneering co-processed excipient based on cellulose-lactose for outstanding compression and flow properties and RetaLac®, the first direct compression co-processed excipient using a hypromellose-lactose base for modified sustained release and controlled release formulations.

About CPhI China 2018

Since Y2000, CPhI China has established itself as the leading pharma industry business and sourcing event for Eastern Asia, reflecting the huge growth of the Chinese pharma market.

Staged by global B2B events organizer and publisher, UBM Live, CPhI China 2018 is a three-day event opening June 20 at the Shanghai New International Exhibition Center (SNIEC).

CPhI China is co-located with five other pharma industry events, P-Mec for machinery and equipment, ICSE for outsourcing solutions BioPh for biotech solution, InnoPack for Drug Packaging and Delivery Technology and LABWorld for laboratory equipment. Together, the shows bring together more than 2,800 suppliers and are likely to attract some 40,000 visitors from more than 100 countries.

CPhI & P-MEC China also part of the wider China Pharma Week, spanning five working days from June 19 that features some 14 events focusing on Business, Knowledge, Leadership, Innovation, Recognition and Networking in the field of Pharma.

More information at: http://www.cphi-china.cn/en.

Media Contact

Margit Bonnetsmüller, Project Manager Marketing, MEGGLE Excipients & Technology Business Group
Tel: +49 8071 73 476
Email: Margit.Bonnetsmueller@meggle.de

OR

Sophie Yao, Technical Manager, MEGGLE Shanghai
Tel: +86 21 33932457
Email: lactose@meggle-china.com

Resources

Click on MEGGLE returns to CPhI China for more information.
Click on MEGGLE to contact the company directly.
Click on MEGGLE – Experts in excipients for CPhI China profile.
Click on MEGGLE Stand for exhibitor info.
Click on Product Configurator to see filtering tool.
Click on MEGGLE on LinkedIn for latest updates.


Supplier Information
Supplier: MEGGLE Excipients & Technology
Address: Megglestrasse 6-12, 83512 Wasserburg, Germany
Tel: +49 8071 73-476
Fax: +49 8071 73-320
Website: https://www.meggle-pharma.com/


MEGGLE shows secrets of longer lactose shelf life at RDD 2018


MEGGLE shows secrets of longer lactose shelf life at RDD 2018


Meggle150x88

Press Release | MEGGLE Excipients & Technology

MAY 24, 2018

Wasserburg, Germany: – Pharmaceutical lactose specialist MEGGLE Excipients & Technology (MEGGLE) demonstrated decisive longer shelf life and storage advantages of its micronized lactose at this year’s Respiratory Drug Delivery (RDD) conference in Tucson, Arizona.

MEGGLE’s micronized dry powder inhaler (DPI) lactose InhaLac® 500 was the star of the display of lactose monohydrate-based pharmaceutical inhalation grade excipients products displayed in Tucson.

Doubled shelf life

MEGGLE also contributed expert insights on how ingredients should be stored, with deliver a Poster presentation on ‘Influence of storage conditions on micronized lactose and the resulting ternary dry powder inhaler formulations’ that examined the effects of water adsorption of water on particle surfaces on the material’s chemical and physical surface properties.

The poster, delivered by MEGGLE’s Head of Research & Development for Excipients & Technology, Dr. Mirjam Kobler, revealed how mastery of these characteristics by the company’s Powder Engineering Team had enabled InhaLac 500 to offer shelf life of 12 months – double that normally expected from micronized lactose.

Storage implications

The study has profound implications for lactose storage in general. It was based on collaboration between MEGGLE, Department of Pharmaceutics and Biopharmaceutics at Germany’s Kiel University and researchers from Istanbul-based Deva Holding AS.

The study team have demonstrated that careful management of relative humidity (rH) during storage can greatly extend the storage life and protect the active properties of micronized lactose and resulting interactive mixtures using different devices.

Research-based understanding

“RDD 2018 was a highly successful event for us”, said MEGGLE USA Business Development Director Rishi Pimentel, who was also part of the RDD team in Tucson.

“We wanted to share with our customer base our expertise in powder engineering and show that MEGGLE remains at the forefront of DPI technology. In InhaLac® 500, we now have a micronized inhalative lactose that is the product of a powder engineering process that is controlled and tailor-made to fit our customer’s metered dose inhalation or MDI formulations,” said Mr. Pimentel.

About MEGGLE Wasserburg

Bavarian-based MEGGLE Wasserburg is one of the world’s experts in lactose based excipients and powder technology.

From its roots as a dairy operation in the late 1880s, MEGGLE has become one of the world’s leading manufacturers of pharmaceutical lactose, supplying the pharma market segment with a broad-based and unique lactose product portfolio.

MEGGLE Excipients & Technology has harnessed outstanding product quality and intelligent innovation to become a global leader in the manufacture of lactose-based excipients, focusing on products for direct tableting and dry powder inhalation.

A multidisciplinary team of committed and highly qualified people allows MEGGLE clients to benefit from pioneering experience and innovative drive in industrial milk and whey processing. The company constantly strives to develop high-tech, functional products for solid dosage form applications, where they can deliver maximum performance.

The company has introduced several pioneering products, notably Tablettose®, the world’s first agglomerated lactose for direct tableting, Cellactose® 80, a pioneering co-processed excipient based on cellulose-lactose for outstanding compression and flow properties and RetaLac®, the first direct compression co-processed excipient using a hypromellose-lactose base for modified sustained release and controlled release formulations.

About RDD 2018

The Respiratory Drug Delivery Conference (RDD) is acknowledged as one of the leading events in the pulmonary, respiratory and nasal delivery fields, helping to shape regulatory and scientific policies worldwide. The conference is biennial, last held in April 2018.

Apart from a full conference program with up to ten scientific tracks, the conference also featured a Scientific Poster Session held in conjunction with the Technology Exhibition over two days.

The event is organized by RDD Online, with more information at:
https://www.rddonline.com/rdd/rdd.php?id=15&sid=1.

Media Contact

Margit Bonnetsmüller, Project Manager Marketing, MEGGLE Excipients & Technology Business Group
Tel: +49 8071 73 476
Email: Margit.Bonnetsmueller@meggle.de

Resources

Click on Review of MEGGLE at RDD 2018 for more information.
Click on MEGGLE to contact the company directly.

m1

Supplier Information
Supplier: MEGGLE Excipients & Technology
Address: Megglestrasse 6-12, 83512 Wasserburg, Germany
Tel: +49 8071 73-476
Fax: +49 8071 73-320
Website: https://www.meggle-pharma.com/


MEGGLE brings advanced DPI and co-processed lactose to FCE Pharma Brazil


MEGGLE brings advanced DPI and co-processed lactose to FCE Pharma Brazil


Meggle150x88

Press Release | MEGGLE Excipients & Technology

MAY 16, 2018

Wasserburg, Germany: – Pharmaceutical lactose specialist MEGGLE Excipients &Technology (MEGGLE) will attend Brazil’s big FCE Pharma expo in São Paulo as an exhibitor.

Once again, MEGGLE will exhibit in partnership with its Brazilian exclusive distributor, Evonik Brasil.

Lactose products and excipients

MEGGLE will use the event to showcase its latest range of lactose-based excipients and services, with particular emphasis on its new generation dry powder inhalation (DPI) and co-processed excipients.

Stars of the MEGGLE display will include the InhaLac® range of sieved, milled and micronized DPI lactose powder excipients, along with Cellactose®80, MicroceLac®100, StarLac®, RetaLac® and CombiLac® lactose-based co-processed excipients.

“Not only is this one of Latin America’s foremost pharmaceutical networking events but also presents us with a great stage from which to display our unrivalled range of lactose-based products and excipients,” said Fábio Luis Ikuno, Managing Director of MEGGLE Latin America, who will lead the team at FCE Pharma.

Web-based configuration

MEGGLE will also use its stand display to introduce end-users to its recently developed web-based Product Configurator that allows customers to identify the correct product by basic applications and characteristics. (See link below).

About MEGGLE Wasserburg

Bavarian-based MEGGLE Wasserburg is one of the world’s experts in lactose based excipients and powder technology.
From its roots as a dairy operation in the late 1880s, MEGGLE has become one of the world’s leading manufacturers of pharmaceutical lactose, supplying the pharma market segment with a broad-based and unique lactose product portfolio.

MEGGLE Excipients & Technology has harnessed outstanding product quality and intelligent innovation to become a global leader in the manufacture of lactose-based excipients, focusing on products for direct tableting and dry powder inhalation.

A multidisciplinary team of committed and highly qualified people allows MEGGLE clients to benefit from pioneering experience and innovative drive in industrial milk and whey processing. The company constantly strives to develop high-tech, functional products for solid dosage form applications, where they can deliver maximum performance.

The company has introduced several pioneering products, notably Tablettose®, the world’s first agglomerated lactose for direct tableting, Cellactose® 80, a pioneering co-processed excipient based on cellulose-lactose for outstanding compression and flow properties and RetaLac®, the first direct compression co-processed excipient using a hypromellose-lactose base for modified sustained release and controlled release formulations.

About FCE Pharma 2018

The FCE Pharma Expo is an annual event that has become a principal marketing, communications and sales platform for the pharmaceutical industry in Latin America. The 23rd FCE Pharma Expo (FCE Brasil 2018) will again be a three-day event opening on May 22 at the São Paulo Expo center in , Brazil.

The 2017 event attracted more than 19,000 visitors and some 500 exhibitors, representing a host of pharmaceutical industry professionals connected with manufacture, supply and distribution of products and services including packaging, labeling, machines and equipment, quality and contamination control, transport and logistics, outsourcing and consultancy, laboratory and analytical equipment, process equipment, valves, sprays, industrial automation, technology and printing services.

The event is organized by Nürnberg Messe Brazil with more information at http://www.fcepharma.com.br/en/.

Media Contact

Margit Bonnetsmüller, Project Manager Marketing, MEGGLE Excipients & Technology Business Group
Tel: +49 8071 73 476
Email: Margit.Bonnetsmueller@meggle.de

OR

Fábio Luis Ikuno, Managing Director , MEGGLE Latin America
Tel: +55 11 2893 4831
Mobile: +55 11 99152 0657
Email: fabio.ikuno@meggle.com

Resources

Click on MEGGLE at FCE Pharma 2018 for more information.
Click on MEGGLE to contact the company directly.
Click on Product Configurator to see MEGGLE filtering tool.
Click on MEGGLE on LinkedIn for latest updates.


Supplier Information
Supplier: MEGGLE Excipients & Technology
Address: Megglestrasse 6-12, 83512 Wasserburg, Germany
Tel: +49 8071 73-476
Fax: +49 8071 73-320
Website: https://www.meggle-pharma.com/


MEGGLE family fights back against leukemia


MEGGLE family fights back against leukemia


Meggle150x88

Press Release | MEGGLE Excipients & Technology

MAY 11, 2018

Wasserburg, Germany: – The entire dairy workforce at German-based pharmaceutical lactose specialist MEGGLE Excipients & Technology (MEGGLE), has banded together to stage an anti-leukemia initiative after one of their number fell victim to the cancer of the blood cells.

When a dairy production worker received a leukemia diagnosis, colleagues banded together to organize a stem cell typification campaign to identify a potential bone marrow donor.

DNA typing

Special typing is necessary to find a genetic twin, whose stem cells could match the patient’s DNA profile. Volunteers give DNA swabs that then can be analyzed in a laboratory. This is the first step to become a potential life saver.

The campaign was led by MEGGLE company physician, Dr. Gertrud Huber, with support from Germany’s bone marrow donor organization, the DKMS.

Joining forces

More than 165 MEGGLE workers participated in the typification campaign. Apprentices, members of Human Resources and the work council joined forces to ensure a fast procedure.

The campaign was publicized via internal notice boards, posters around the factory site and group mailings.

Spreading the message

“Direct talks at the canteen and car park during the shift change encouraged more people to participate in the typification,” said MEGGLE Human Resources Director, Doris Kollmannsberger.

“We hope that we are now able to help our colleague and maybe other patients with this disease. At the very least, we have alerted our people to the risks of leukemia and blood cancer, ‘ said Ms. Kollmannsberger.

“A few of our employees were already registered as potential donors and so didn’t need to be typified again,” she explained.

About MEGGLE Wasserburg

Bavarian-based MEGGLE Wasserburg is one of the world’s experts in lactose based excipients and powder technology.

From its roots as a dairy operation in the late 1880s, MEGGLE has become one of the world’s leading manufacturers of pharmaceutical lactose, supplying the pharma market segment with a broad-based and unique lactose product portfolio.

MEGGLE Excipients & Technology has harnessed outstanding product quality and intelligent innovation to become a global leader in the manufacture of lactose-based excipients, focusing on products for direct tableting and dry powder inhalation.

A multidisciplinary team of committed and highly qualified people allows MEGGLE clients to benefit from pioneering experience and innovative drive in industrial milk and whey processing. The company constantly strives to develop high-tech, functional products for solid dosage form applications, where they can deliver maximum performance.

The company has introduced several pioneering products, notably Tablettose®, the world’s first agglomerated lactose for direct tableting, Cellactose® 80, a pioneering co-processed excipient based on cellulose-lactose for outstanding compression and flow properties and RetaLac®, the first direct compression co-processed excipient using a hypromellose-lactose base for modified sustained release and controlled release formulations.

Media Contact

Margit Bonnetsmüller, Project Manager Marketing, MEGGLE Excipients & Technology Business Group
Tel: +49 8071 73 476
Email: Margit.Bonnetsmueller@meggle.de

Resources

Click on MEGGLE leukemia campaign for more information.
Click on MEGGLE to contact the company directly.

MEGGLE employees volunteered to be DNA swabbed to identify bone marrow donor

MEGGLE employees volunteered to be DNA swabbed to identify bone marrow donor


Supplier Information
Supplier: MEGGLE Excipients & Technology
Address: Megglestrasse 6-12, 83512 Wasserburg, Germany
Tel: +49 8071 73-476
Fax: +49 8071 73-320
Website: https://www.meggle-pharma.com/


MEGGLE brings expert insights to RDD respiratory conference


MEGGLE brings expert insights to RDD respiratory conference


Meggle150x88

Press Release | MEGGLE Excipients & Technology

APRIL 18, 2018

Wasserburg, Germany: – Pharmaceutical lactose specialist MEGGLE Excipients & Technology (MEGGLE) is returning as a sponsor and exhibitor to the influential Respiratory Drug Delivery Conference, this year in Tucson, Arizona.

MEGGLE will bring to the event a selected range of inhalation quality lactose grades as well as expert knowledge.

Sponsor and Exhibitor

MEGGLE is attending regularly the RDD conference since 2013. For RDD Arizona, it will be both a Silver Sponsor and Exhibitor. At the technical exhibition MEGGLE will showcase their distinguished portfolio, in particular products suitable for dry powder inhalation at table 3.

MEGGLEs scientifically present with a Poster with the title “Influence of storage conditions on micronized lactose and the resulting ternary dry powder inhaler formulations” that examines the effect of water adsorption on the material’s chemical and physical surface properties.

Storage management

The study was the result of collaboration between MEGGLE, the Department of Pharmaceutics and Biopharmaceutics at Germany’s Kiel University and researchers from Istanbul-based Deva Holding AS.

It demonstrates that careful management of relative humidity (rH) during storage can either positively or negatively influence the active properties of micronized lactose and the resulting interactive mixtures using different devices.

Latest trends

Along with Dr. Kobler, MEGGLE will be represented by two colleagues from MEGGLE USA; Director Ken Seufert and Business Development Director Rishi Pimentel.

“RDD Arizona 2018 will provide us with an ideal platform from which to present our product portfolio, meet leading customers and expert peers and explore latest trends in the respiratory and nasal delivery fields,” commented Dr. Kobler.

About MEGGLE Wasserburg

Bavarian-based MEGGLE Wasserburg is one of the world’s experts in lactose based excipients and powder technology.

From its roots as a dairy operation in the late 1880s, MEGGLE has become one of the world’s leading manufacturers of pharmaceutical lactose, supplying the pharma market segment with a broad-based and unique lactose product portfolio.

MEGGLE Excipients & Technology has harnessed outstanding product quality and intelligent innovation to become a global leader in the manufacture of lactose-based excipients, focusing on products for direct tableting and dry powder inhalation.

A multidisciplinary team of committed and highly qualified people allows MEGGLE clients to benefit from pioneering experience and innovative drive in industrial milk and whey processing. The company constantly strives to develop high-tech, functional products for solid dosage form applications, where they can deliver maximum performance.

The company has introduced several pioneering products, notably Tablettose®, the world’s first agglomerated lactose for direct tableting, Cellactose® 80, a pioneering co-processed excipient based on cellulose-lactose for outstanding compression and flow properties and RetaLac®, the first direct compression co-processed excipient using a hypromellose-lactose base for modified sustained release and controlled release formulations.

About RDD 2018

The Respiratory Drug Delivery Conference (RDD) is acknowledged as one of the leading events in the pulmonary, respiratory and nasal delivery fields, helping to shape regulatory and scientific policies worldwide.

RDD 2018 is a five-day event opening April 22 at the JW Marriott Starr Pass Resort and Spa in Tucson, Arizona.

Apart from a full conference program with up to ten scientific tracks, the conference also features a Scientific Poster Session held in conjunction with the Technology Exhibition over two days.

The event is organized by RDD Online, with more information at: https://www.rddonline.com/rdd/rdd.php?id=15&sid=1.

Media Contact

Margit Bonnetsmüller, Project Manager Marketing, MEGGLE Excipients & Technology Business Group
Tel: +49 8071 73 476
Email: Margit.Bonnetsmueller@meggle.de

Resources

Click on MEGGLE at RDD Arizona 2018 for more information.
Click on MEGGLE to contact the company directly.

m1


Supplier Information
Supplier: MEGGLE Excipients & Technology
Address: Megglestrasse 6-12, 83512 Wasserburg, Germany
Tel: +49 8071 73-476
Fax: +49 8071 73-320
Website: https://www.meggle-pharma.com/


MEGGLE AG appoints three new directors to Management Board


MEGGLE AG appoints three new directors to Management Board


Meggle150x88

Press Release | MEGGLE Excipients & Technology

APRIL 03, 2018

Wasserburg, Germany: – MEGGLE have appointed three new directors to their Management board. From 1st of March 2018, Marcus Hormuth (47) and Matthias Oettel (52) and from 1st of April 2018 Dr. Stefan Schmale (55), three more experts join the Board of the dairy factory in Wasserburg. Together with CEO Reinhold Schlensok they will lead the family company into the future. All three have been recruited from outside the company.

MEGGLE have also appointed Prof. Bruno Meiser, MD, currently Head of the Transplantation Centre Munich of the LMU, to its Supervisory Board, joining Toni Meggle (Chairman), Prof. Dr. Claus Hipp (deputy Chairman) and Marina Meggle.

Generation change

Toni Meggle, owner and Chairman of the Supervisory Board at MEGGLE, commented: “As planned, this is the next step for a successful future of MEGGLE. The generation change, which started with the appointment of Reinhold Schlensok, has now been completed.”

CEO Reinhold Schlensok added: “I’m pleased that with Marcus Hormuth, Matthias Oettel and Dr. Stefan Schmale we have been able to bring three highly experienced managers onto the MEGGLE Board.”

“With this new and experienced team, we will continue to lead MEGGLE successfully into the future,” said Mr. Schlensok.

Marcus Hormuth

Marcus Hormuth, 47, is returning to MEGGLE as Director of the Functional Products business division after more than four years away, as Director for International Sales at Street One GmbH. Previously, he worked for the MEGGLE dairy company between 2000 and 2013, beginning his career as Sales Manager in Wasserburg before establishing the MEGGLE sites in Singapore and White Plains, USA.

Matthias Oettel

Until most recently Matthias Oettel worked as Director Sales & Marketing at Zott SE & Co. KG and was responsible for D-A-CH-Region, Northern, Western and Southern Europe. Before joining Zott, Mr. Oettel, 52, acted in key positions for Bel Deutschland GmbH, Nöm International AG in Austria and Danone GmbH. As member of the MEGGLE Board, he will now be responsible for Consumer Products.

Dr. Stefan Schmale

Dr. Stefan Schmale, 55, spent more than eight years as commercial Managing Director at Paulaner Brauerei GmbH & Co. KG in Munich. His previous experience includes various financial management positions at VIAG AG Group, Creatogen AG and Schaeffler KG. As Chief Financial Officers (CFO) of MEGGLE AG, he will be responsible for Controlling, Finance and IT.

About MEGGLE Wasserburg

Bavarian-based MEGGLE Wasserburg is one of the world’s experts in lactose based excipients and powder technology.

From its roots as a dairy operation in the late 1880s, MEGGLE has become one of the world’s leading manufacturers of pharmaceutical lactose, supplying the pharma market segment with a broad-based and unique lactose product portfolio.

MEGGLE Excipients & Technology has harnessed outstanding product quality and intelligent innovation to become a global leader in the manufacture of lactose-based excipients, focusing on products for direct tableting and dry powder inhalation.

A multidisciplinary team of committed and highly qualified people allows MEGGLE clients to benefit from pioneering experience and innovative drive in industrial milk and whey processing. The company constantly strives to develop high-tech, functional products for solid dosage form applications, where they can deliver maximum performance.

The company has introduced several pioneering products, notably Tablettose®, the world’s first agglomerated lactose for direct tableting, Cellactose® 80, a pioneering co-processed excipient based on cellulose-lactose for outstanding compression and flow properties and RetaLac®, the first direct compression co-processed excipient using a hypromellose-lactose base for modified sustained release and controlled release formulations.

Media Contact

Margit Bonnetsmüller, Project Manager Marketing, MEGGLE Excipients & Technology Business Group
Tel: +49 8071 73 476
Email: Margit.Bonnetsmueller@meggle.de

Resources

Click on MEGGLE Management Board changes for more information.
Click on MEGGLE to contact the company directly.

MEGGLE Management Board (from left): Marcus Hormuth, Reinhold Schlensok, Matthias Oettel, Dr. Stefan Schmale, Marina Meggle, Toni Meggle, Prof. Dr. med. Bruno Meiser

MEGGLE Management Board (from left): Marcus Hormuth, Reinhold Schlensok, Matthias Oettel, Dr. Stefan Schmale, Marina Meggle, Toni Meggle, Prof. Dr. med. Bruno Meiser


Supplier Information
Supplier: MEGGLE Excipients & Technology
Address: Megglestrasse 6-12, 83512 Wasserburg, Germany
Tel: +49 8071 73-476
Fax: +49 8071 73-320
Website: https://www.meggle-pharma.com/


MEGGLE returns to PBP World Meeting with mini tablet details


MEGGLE returns to PBP World Meeting with mini tablet details


Meggle150x88

Press Release | MEGGLE Excipients & Technology

MARCH 16, 2018

Wasserburg, Germany: – Pharmaceutical lactose specialist MEGGLE Excipients & Technology (MEGGLE) is returning as an exhibitor to the 11th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology (PBP 2018) in Granada, Spain.

MEGGLE has attended every PBP World Meeting since the biennial event was first staged in 1996.

The MEGGLE stand at Booth 17 at Granada’s PECG congress center will present highlights from the company’s huge range of lactose-based ingredients and excipients.

Mini-tablets poster

MEGGLE will also present a poster entitled: Development of Mini-tablets Containing 10 % Vitamin B2 and C: Characterization and Tableting Performance.

The mini tablets were developed in co-operation with Italian-based IMA Active S.p.A, whose scientists Anastasiya Zakhvatayeva, Federica Giatti and Caterina Funaro joined MEGGLE’s Vera Fichtner and Franz Karl Penz, Head of Application Technology, in authoring the paper on the new formulation.

Growing use

The use of mini-tablets continues to grow as an accepted option for small volume, high-value products, especially for specific patient populations. Single or multi-unit mini-tablet applications have the advantages of allowing fixed combinations and dose titrations.

“Furthermore, the typical diameter below three millimeters offers a superior approach for special populations like pediatric and geriatric patients or patients suffering from dysphagia.

The joint IMA/MEGGLE study aimed to demonstrate experimental design, equipment feasibility, lactose-based material performance, and critical material attributes within a typical mini-tablet manufacturing operation using an 8-station Prexima® 80 rotary press. Example formulations selected two different APIs and three functional excipients, Combi-Lac®, RetaLac® and spray-dried lactose, FlowLac® 100, to investigate compaction and release performances, as well as the impact of particle size.

Satisfactory performance

The poster shows how all materials showed performance within expected ranges when compactibility, tablet mass uniformity, and Vitamin B2 API release were investigated. Amongst other material specific properties, blend flowability was confirmed to be critical for tablet weight uniformity. Indirect correlation to API particle size was demonstrated for the investigated Vitamin B2 and C systems. Retesting mini-tablets after one month at 25 °C, and 60% RH showed no significant changes in tablet diameter or thickness. Breaking force variations were slightly larger.

Results clearly demonstrated equipment feasibility and material performance.

“We are looking forward to returning to the World Meeting to present this poster, as well as the opportunity to present our product portfolio, meet existing and potential customers and explore latest industry trends” Dr. Penz concluded.

About MEGGLE Wasserburg

Bavarian-based MEGGLE Wasserburg is one of the world’s experts in lactose based excipients and powder technology.

From its roots as a dairy operation in the late 1880s, MEGGLE has become one of the world’s leading manufacturers of pharmaceutical lactose, supplying the pharma market segment with a broad-based and unique lactose product portfolio.

MEGGLE Excipients & Technology has harnessed outstanding product quality and intelligent innovation to become a global leader in the manufacture of lactose-based excipients, focusing on products for direct tableting and dry powder inhalation.

A multidisciplinary team of committed and highly qualified people allows MEGGLE clients to benefit from pioneering experience and innovative drive in industrial milk and whey processing. The company constantly strives to develop high-tech, functional products for solid dosage form applications, where they can deliver maximum performance.

The company has introduced several pioneering products, notably Tablettose®, the world’s first agglomerated lactose for direct tableting, Cellactose® 80, a pioneering co-processed excipient based on cellulose-lactose for outstanding compression and flow properties and RetaLac®, the first direct compression co-processed excipient using a hypromellose-lactose base for modified sustained release and controlled release formulations.

About PBP 2018

The Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology (PBP) World Meeting has become a well-established pharma industry event, attracting scientists from all over the world. The event is biennial, with previous meetings held in Budapest, Paris, Berlin, Florence, Geneva, Barcelona, Malta, Istanbul, Lisbon, and Glasgow (2016).

The 11th World Meeting, PBP 2018, is a four-day event opening March 19 at the Palacio de Exposiciones y Congressos (PECG) in Granada, Spain.

The event is expected to attract more than 1,300 delegates with close to 1,000 abstracts posted.

The conference and the accompanying ResearchPharm® exhibition provide a cross-disciplinary platform for pharmaceutical scientists working in all fields of drug product development in industry, academia and regulation.

PBP 2016 will have parallel sessions on industry-related topics presented by distinguished invited speakers along with two further parallel tracks for oral presentations by young or established scientists on Pharmaceutics, Biopharmaceutics and Pharma Technology.

More information at: http://www.worldmeeting.org/home.

Media Contact

Margit Bonnetsmüller, Project Manager Marketing, MEGGLE Excipients & Technology Business Group
Tel: +49 8071 73 476
Email: Margit.Bonnetsmueller@meggle.de

Resources

Click on MEGGLE at PBP 2018 for more information.
Click on MEGGLE to contact the company directly.

MEGGLE/IMA Vitamin B2 and Vitamin C mini tablets are under 3 mm in diameter.  MEGGLE/IMA Vitamin B2 and Vitamin C mini tablets are under 3 mm in diameter. [/caption]

Supplier Information
Supplier: MEGGLE Excipients & Technology
Address: Megglestrasse 6-12, 83512 Wasserburg, Germany
Tel: +49 8071 73-476
Fax: +49 8071 73-320
Website: https://www.meggle-pharma.com/


MEGGLE returns to DDL 2017 with enhanced inhalation offers


MEGGLE returns to DDL 2017 with enhanced inhalation offers


Meggle150x88

Press Release | MEGGLE Excipients & Technology

NOVEMBER 29, 2017

Wasserburg, Germany: – Pharmaceutical lactose specialist MEGGLE Excipients & Technology (MEGGLE) is returning as an exhibitor to the Drug Delivery to the Lungs (DDL) Conference in Edinburgh, showcasing its expanded range of lactose anhydrous and lactose monohydrate-based inhalation agents and excipients.

For the fifth year in succession, MEGGLE will be a DDL exhibitor with a stand at Booth 234 at the Edinburgh International Conference Center (EICC) featuring a display showcasing latest developments.

Micronized inhalation lactose

The stand will feature the enhanced properties of MEGGLE products, including its newly developed micronized lactose grade InhaLac 500, specifically designed for inhalation.

Developed at MEGGLE’s Wasserburg laboratories in Germany, InhaLac 500 features very small milled particles, high cohesive properties and even distribution, with 90% of the particles being smaller than 10 μm (x50 ≤ 5 μm). This allows a wider choice of applications as fines or as co-agglomerate in dry powder inhalation products. A further key benefit is long shelf life, with high stability reducing retest intervals to 12 months, twice as long as competitor products.

Storage insights

“We have a long and proud relationship with DDL, having attended since more than 10 years and contributing many posters and sponsorships,” said Eugen Schwarz, MEGGLE Head of Research & Development.

Once again, MEGGLE will provide significant input to the conference agenda, with a poster on “Influence of the storage conditions on tenary powder mixtures” based on research by M. Hertel and others in MEGGLE’s Wasserburg laboratories.

The MEGGLE presence in Edinburgh will be complemented by Sabine Hauptsteinand Diana Kesetovic, Project Manager for Dry Powder Inhalers.

About MEGGLE Wasserburg

Bavarian-based MEGGLE Wasserburg is one of the world’s experts in lactose based excipients and powder technology.

From its roots as a dairy operation in the late 1880s, MEGGLE has become one of the world’s leading manufacturers of pharmaceutical lactose, supplying the pharma market segment with a broad-based and unique lactose product portfolio.

MEGGLE Excipients & Technology has harnessed outstanding product quality and intelligent innovation to become a global leader in the manufacture of lactose-based excipients, focusing on products for direct tableting and dry powder inhalation.

A multidisciplinary team of committed and highly qualified people allows MEGGLE clients to benefit from pioneering experience and innovative drive in industrial milk and whey processing. The company constantly strives to develop high-tech, functional products for solid dosage form applications, where they can deliver maximum performance.

The company has introduced several pioneering products, notably Tablettose®, the world’s first agglomerated lactose for direct tableting, Cellactose® 80, a pioneering co-processed excipient based on cellulose-lactose for outstanding compression and flow properties and RetaLac®, the first direct compression co-processed excipient using a hypromellose-lactose base for modified sustained release and controlled release formulations.

About DDL 2017

The Drug Delivery to the Lungs Conference (DDL) provides an annual forum for scientists, academics, clinicians, regulatory and industry specialists involved in developing medicines for inhalation.

DDL2017 is a three-day event opening December 6 at the EICC at The Exchange in the Scottish capital of Edinburgh.

The 2017 conference will feature five themed sessions each with a combination of invited and submitted lectures given by experts in the field of inhalation and students working to advance respiratory science.

The conference will be preceded by the SimInhale Pre-symposium on designing Inhalers for children and Infants, during the morning of Wednesday, December 6.

The event is organized by The Aerosol Society, with more information at: https://aerosol-soc.com/events/ddl2017.

Media Contact

Margit Bonnetsmüller, Project Manager Marketing, MEGGLE Excipients & Technology Business Group
Tel: +49 8071 73 476
Email: Margit.Bonnetsmueller@meggle.de

Resources

Click on MEGGLE at DDL 2017 for more information.
Click on MEGGLE to contact the company directly.
Click on InhaLac 500 for product information.


Supplier Information
Supplier: MEGGLE Excipients & Technology
Address: Megglestrasse 6-12, 83512 Wasserburg, Germany
Tel: +49 8071 73-476
Fax: +49 8071 73-320
Website: https://www.meggle-pharma.com/


MEGGLE debuts InhaLac® 500 at CPhI India


MEGGLE debuts InhaLac® 500 at CPhI India


Meggle150x88

Press Release | MEGGLE Excipients & Technology

NOVEMBER 14, 2017

Wasserburg, Germany: – Pharmaceutical lactose specialist MEGGLE Excipients & Technology (MEGGLE) will bring an expanded range of lactose anhydrous and lactose monohydrate-based pharmaceutical agents and excipients when it returns to the huge CPhI India expo in Mumbai.

MEGGLE will display under the banner of its Indian distribution partner, Signet Chemical Corporation, at stand F1 in Hall 1 of the Bombay Exhibition Center.

Showcasing InhaLac 500

In particular, the MEGGLE display will feature its newly developed InhaLac 500, the new micronized lactose grade, specifically designed for inhalation.

Developed at MEGGLE’s Wasserburg laboratories in Germany, InhaLac 500 features very small milled particles, highly cohesive, with PSD x90≤ 10µmx50 ≤ 5 μm. This allows a wider choice of applications as fines or as co-agglomerate in dry powder inhalation products. A further key benefit is long shelf life, with high stability reducing retest intervals to 12 months, twice as long as competitor products.

Established Indian presence

MEGGLE has become an established presence at CPhI India, having exhibited year on year almost since the event was founded in 2005.

“This amazing event gives us a great platform from which to conduct strategic sales discussions with leading customers across Asia and to showcase new products,” said Dr. Siang Meng Chua, of MEGGLE Singapore, who heads sales and technical support for MEGGLE’s pharmaceutical grade lactoses in Asia-Pac Ex China.

“For procurement and sourcing department heads, this is a great chance to discuss their supply requirements for the year ahead and for formulators of solid dosage forms, an opportunity to get face-to-face technical guidance on enhanced functionality for co-processed excipients to streamline and speed up their formulation development processes,” noted Dr. Chua.

About MEGGLE Wasserburg

Bavarian-based MEGGLE Wasserburg is one of the world’s experts in lactose based excipients and powder technology.

From its roots as a dairy operation in the late 1880s, MEGGLE has become one of the world’s leading manufacturers of pharmaceutical lactose, supplying the pharma market segment with a broad-based and unique lactose product portfolio.

MEGGLE Excipients & Technology has harnessed outstanding product quality and intelligent innovation to become a global leader in the manufacture of lactose-based excipients, focusing on products for direct tableting and dry powder inhalation.

A multidisciplinary team of committed and highly qualified people allows MEGGLE clients to benefit from pioneering experience and innovative drive in industrial milk and whey processing. The company constantly strives to develop high-tech, functional products for solid dosage form applications, where they can deliver maximum performance.

The company has introduced several pioneering products, notably Tablettose®, the world’s first agglomerated lactose for direct tableting, Cellactose® 80, a pioneering co-processed excipient based on cellulose-lactose for outstanding compression and flow properties and RetaLac®, the first direct compression co-processed excipient using a hypromellose-lactose base for modified sustained release and controlled release formulations.

About CPhI India 2017

Now in its twelfth year, the huge CPhI India pharmaceutical industry expo brings the highly successful worldwide UBM-organized franchise to one of the world’s biggest single pharma markets, combining two events in one, with the event co-hosted alongside the huge P-MEC machinery and equipment show.

CPhI/P-MEC India 2017 will be a six-day event shared between two venues, opening November 27 at the landmark Bombay Exhibition Centre (BEC) in Mumbai, followed by an opening the next day at the BKC center.

The combined shows are expected to attract more than 28,000 visitors and some 1,000 exhibitors from almost 100 countries worldwide.

CPhI India bills itself as serving the knowledge sharing and networking needs of the Indian pharma market, currently growing at 13 per cent annually, twice as fast as world average. India is adding new drugs research to its established strengths in generics and APIs.

The event is organized by UBM Live, with more information at: https://www.cphi.com/india/.

Media Contact

Margit Bonnetsmüller, Project Manager Marketing, MEGGLE Excipients & Technology Business Group
Tel: +49 8071 73 476
Email: service.pharma@meggle.de

Resources

Click on MEGGLE at CPhI India 2017 for more information.
Click on MEGGLE to contact the company directly.


Supplier Information
Supplier: MEGGLE Excipients & Technology
Address: Megglestrasse 6-12, 83512 Wasserburg, Germany
Tel: +49 8071 73-476
Fax: +49 8071 73-320
Website: https://www.meggle-pharma.com/


MEGGLE brings InhaLac® 500 to CPhI Worldwide


MEGGLE brings InhaLac® 500 to CPhI Worldwide


Meggle150x88

Press Release | MEGGLE Excipients & Technology

OCTOBER 09, 2017

Wasserburg, Germany: – Pharmaceutical lactose specialist MEGGLE Excipients & Technology (MEGGLE) will return as an exhibitor to the CPhI Worldwide expo in Frankfurt with an expanded range of lactose-based pharmaceutical excipients.

MEGGLE is one of CPhI’s most established exhibitors, having attended every worldwide expo for more than 20 years, almost since the event was initially founded in 1991.

“Once again we will be taking advantage of this exhibition to reach out to our important existing and potential business partners and to present our product portfolio, now significantly enhanced with the addition of our latest product InhaLac® 500,” said Christoph Adler, Area Manager & Project Manager Marketing.

The experts of MEGGLE are looking forward welcome you on the MEGGLE stand 11.OF32.

High cohesion and stability

Developed at MEGGLE’s Wasserburg laboratories in Germany, InhaLac 500 is MEGGLE´s first micronized lactose grade, specifically designed for inhalation with extremely small particles. Combined with high quality and safety, it meets the most demanding individual dry powder inhalation formulation requirements.

The micronization process used for InhaLac® 500 produces very small particles, high cohesive properties and even distribution, with 90% of the particles being smaller than 10 μm.

InhaLac® 500 exhibits a similar size as active pharmaceutical ingredients (APIs). This makes it very versatile across a wide range of applications
In summary, InhaLac 500 offers a potent range of overall benefits:

  • Improvement of fine particle fractions (FPF) when used in ternary mixtures
  • saturation of active sites
  • co-agglomeration with drug particles etc.
  • x90 less than 10 µm
  • Highly Cohesive
  • High stability

Distinctive booth

Once again, MEGGLE’s stand will be instantly recognizable for its ‘moss-covered’ look, symbolizing the company’s core values of sustainability, tradition and innovation. As with the previous stand at CPhI 2016 in Barcelona, the stand will combine a showcase of the company’s product portfolio with a comfortable area to host face-to-face meetings.

MEGGLE is currently accepting bookings for meetings during CPhI Worldwide.

About MEGGLE Wasserburg

Bavarian-based MEGGLE Wasserburg is one of the world’s experts in lactose based excipients and powder technology.

From its roots as a dairy operation in the late 1880s, MEGGLE has become one of the world’s leading manufacturers of pharmaceutical lactose, supplying the pharma market segment with a broad-based and unique lactose product portfolio.

MEGGLE Excipients & Technology has harnessed outstanding product quality and intelligent innovation to become a global leader in the manufacture of lactose-based excipients, focusing on products for direct tableting and dry powder inhalation.

A multidisciplinary team of committed and highly qualified people allows MEGGLE clients to benefit from pioneering experience and innovative drive in industrial milk and whey processing. The company constantly strives to develop high-tech, functional products for solid dosage form applications, where they can deliver maximum performance.

The company has introduced several pioneering products, notably Tablettose®, the world’s first agglomerated lactose for direct tableting, Cellactose® 80, a pioneering co-processed excipient based on cellulose-lactose for outstanding compression and flow properties and RetaLac®, the first direct compressible co-processed excipient using a hypromellose-lactose base for modified release formulations.

About CPhI Worldwide 2017

CPhI Worldwide is the flagship annual trade show for pharma ingredients and partner sourcing providing delegates and exhibitors networking opportunities with potential international pharmaceutical partners and collaborators, as well as latest industry insights.

Now in its 28th year, CPhI 2017 is a three-day event opening October 24 at the Messe Frankfurt exhibition center. Last year’s event in Barcelona attracted some 42,000 delegates and more than 2,500 exhibitor companies from 155 countries worldwide.

CPhI Worldwide is held alongside four other zoned exhibitions; ICSE Outsourcing solutions, P-MEC Machinery and Equipment, InnoPack pharmaceutical packaging and a new addition, the FDF show for Finished Dosage & Formulations, bringing together every aspect of the finished dosage supply chain.

The CPhI series is staged by leading Global B2B Events Organizer and Publisher UBM Live More information at: http://www.cphi.com/europe/

Media Contact

Margit Bonnetsmüller, Project Manager Marketing, MEGGLE Excipients &Technology Business Group
Tel: +49 8071 73 476
Email: service.pharma@meggle.de

Resources

Click on MEGGLE brings InhaLac® 500 to CPhI Worldwide for more information.
Click on MEGGLE to contact the company directly.

MEGGLE’s stand at CPhI Frankfurt will once again feature the ‘moss-covered’ look of its booth at CPhI Barcelona 2016

MEGGLE’s stand at CPhI Frankfurt will once again feature the ‘moss-covered’ look of its booth at CPhI Barcelona 2016

MEGGLE’s lounge at CPhI Worldwide 2017 will again provide a comfortable area for meetings

MEGGLE’s lounge at CPhI Worldwide 2017 will again provide a comfortable area for meetings


Supplier Information
Supplier: MEGGLE Excipients & Technology
Address: Megglestrasse 6-12, 83512 Wasserburg, Germany
Tel: +49 8071 73-476
Fax: +49 8071 73-320
Website: https://www.meggle-pharma.com/


MEGGLE researchers demonstrate superior water uptake for CombiLac®


MEGGLE researchers demonstrate superior water uptake for CombiLac®


Meggle150x88

Press Release | MEGGLE Excipients & Technology

AUGUST 10, 2017

Wasserburg, Germany: – Pharmaceutical lactose specialist MEGGLE Excipients &Technology (MEGGLE) has performed a research study demonstrating how its new co-processed excipient CombiLac® is characterized by improved water uptake behavior via Dynamic Vapor Sorption (DVS).

The study was authored by a multinational team of MEGGLE researchers, comprising; Dr. Mirjam E. Dogru, Dr. Vera Fichtner, Ilona L. Pescher, Dr. Christian Nowak and Dr. Franz K. Penz at the MEGGLE Excipients & Technology laboratories at Wasserburg, Germany, assisted by Joseph A. Zeleznik from MEGGLE USA, Inc.

Study objectives

The purpose of the study was to demonstrate the impact of appropriate excipient selection in significantly reducing or preventing the water uptake than can lead to changes in the physical form, functional performance, or chemical stability of many APIs through effects such as degradation by hydrolysis.

These changes can impact API performance during solid dosage form development and manufacture.

The study focused on examining the water sorption characteristics of CombiLac® as a new, co-processed, directly compressible excipient that comprises α-lactose monohydrate (70 %), MCC (20 %) and native maize starch (10 %), in comparison to various physical admixtures (PAMs) having equivalent composition.

Gravimetric monitoring

The team used Dynamic Vapor Sorption to gravimetrically monitor moisture up-take by of different samples over a range of temperatures and relative humidifies (R.H.).

Each sample was dried at 0 % R.H. until constant mass was reached. Two cycles were performed on each sample steadily increasing R.H. up to 90 %.

The team examined a range of materials including three CombiLac® batches and a variety of physical admixtures (PAMs) of equivalent composition: including spray- dried (SD) lactose, pregelatinized starch, milled lactose grade and native maize starch.

Reproducible results

They observed consistent moisture uptake reproducibility (30, 50, 90% R.H.) in the three co-processed lactose-based excipient (CombiLac®) lots with maximum RSD of less than 3%.

A performance comparison showed that co-processed excipient demonstrated superior moisture uptake capacity compared to the PAMs. This effect was clearly evident over the entire water sorption range investigated using equilibrium and non-equilibrium conditions. “This was attributed to the individual component physical properties, including particle size. Kinetics in dm [%] after leaving equilibrium conditions have been recorded and fitted for various relative humidities,” the study observes.

Greater API stability

In conclusion, the team comments:

“DVS results showed that co-processing lactose, MCC, and maize starch was successful in creating an excipient having improved moisture sorption properties superior to a physical admixture having equivalent composition. Water sorption behavior may be tailored to enhance the protective performance of an excipient, which may provide greater API stability.”

The study is available to download from the MEGGLE Excipients & Technology website (see Resources below).

About MEGGLE Wasserburg

Bavarian-based MEGGLE Wasserburg is one of the world’s experts in lactose based excipients and powder technology.

From its roots as a dairy operation in the late 1880s, MEGGLE has become one of the world’s leading manufacturers of pharmaceutical lactose, supplying the pharma market segment with a broad-based and unique lactose product portfolio.

MEGGLE Excipients & Technology has harnessed outstanding product quality and intelligent innovation to become a global leader in the manufacture of lactose-based excipients, focusing on products for direct tableting and dry powder inhalation.

A multidisciplinary team of committed and highly qualified people allows MEGGLE clients to benefit from pioneering experience and innovative drive in industrial milk and whey processing. The company constantly strives to develop high-tech, functional products for solid dosage form applications, where they can deliver maximum performance.

The company has introduced several pioneering products, notably Tablettose®, the world’s first agglomerated lactose for direct tableting, Cellactose® 80, a pioneering co-processed excipient based on cellulose-lactose for outstanding compression and flow properties and RetaLac®, the first direct compressible co-processed excipient using a hypromellose-lactose base for modified release formulations.

Media Contact

Margit Bonnetsmüller, Project Manager Marketing
Tel: +49 8071 73 476
Email: service.pharma@meggle.de

Resources

Click on MEGGLE CombiLac® research study for more information.
Click on MEGGLE to contact the company directly.
Click on Characterization of CombiLac® for Direct Compression by DVS to download the study.

Typical DVS relative mass change (water sorption) versus R.H. change

Typical DVS relative mass change (water sorption) versus R.H. change

CombiLac® (green lines) demonstrated an overall superior moisture uptake capacity over equivalent PAMs

CombiLac® (green lines) demonstrated an overall superior moisture uptake capacity over equivalent PAMs


Supplier Information
Supplier: MEGGLE Excipients & Technology
Address: Megglestrasse 6-12, 83512 Wasserburg, Germany
Tel: +49 8071 73-476
Fax: +49 8071 73-320
Website: https://www.meggle-pharma.com/


MEGGLE Direct Cost revels hidden savings from Direct Compression tableting


MEGGLE Direct Cost revels hidden savings from Direct Compression tableting


Meggle150x88

Press Release | MEGGLE Excipients & Technology

JULY 03, 2017

Wasserburg, Germany: – Pharmaceutical lactose specialist MEGGLE Excipients &Technology (MEGGLE) has launched DirectCost as a web-based calculation tool designed to help customers optimize their tableting process.

“There are two main methods of producing a tablet: either using a wet granulation [WG] process or via a direct compression [DC] process,” explains MEGGLE Project Manager Marketing, Christoph Adler.

Wet granulation vs. direct compression

“Wet granulation is probably the most popular method for tablet production but it has many more production steps compared to direct compression. If your formulation is suitable for direct compression a reduction of processing time, labor, energy and validations costs can be achieved.” said Mr. Adler.

“The more economic way is to produce via direct compression, where the marginal costs of premium ingredients like agglomerated, spray-dried or co-processed lactose excipients can be far outweighed by reducing production steps and ultimate time savings,” he pointed out.

Cost benefit analysis

“DirectCost will allow our customer base of purchasing managers and R&D scientists to directly compare DC and WG processes for the same formulation to see whether switching from cheaper wet granulation excipients to the more expensive direct compressible ingredients could in fact save significant amounts of money over the long term,” said Mr. Adler.

DirectCost provides an easy way to compare wet granulation with direct compression, allowing rapid assessment of the cost and time saving potential of a selected formulation.

Free access

MEGGLE has designed DirectCost as a simple to use tool to calculate the cost/savings ratio and ultimate benefit, offering complete flexibility on batch size and process steps. Six different example formulations will showcase the functionality of the tool.

It provides immediate graphical visualizations and reports and can be run offline on a wide variety of PC and mobile platforms, with results saved locally or to the cloud.

MEGGLE is offering full access to DirectCost free of charge to all its registered customers and is planning a series of online tutorials and webinars to explain how to get the best results from the tool.

About MEGGLE Wasserburg

Bavarian-based MEGGLE Wasserburg is one of the world’s experts in lactose based excipients and powder technology.

From its roots as a dairy operation in the late 1880s, MEGGLE has become one of the world’s leading manufacturers of pharmaceutical lactose, supplying the pharma market segment with a broad-based and unique lactose product portfolio.

MEGGLE Excipients & Technology has harnessed outstanding product quality and intelligent innovation to become a global leader in the manufacture of lactose-based excipients, focusing on products for direct tableting and dry powder inhalation.

A multidisciplinary team of committed and highly qualified people allows MEGGLE clients to benefit from pioneering experience and innovative drive in industrial milk and whey processing. The company constantly strives to develop high-tech, functional products for solid dosage form applications, where they can deliver maximum performance.

The company has introduced several pioneering products, notably Tablettose®, the world’s first agglomerated lactose for direct tableting, Cellactose® 80, a pioneering co-processed excipient based on cellulose-lactose for outstanding compression and flow properties and RetaLac®, the first direct compressible co-processed excipient using a hypromellose-lactose base for modified release formulations.

Media Contact

Christoph Adler, Area Manager & Project Manager Marketing
Tel: +49 8071 73 471
Email: christoph.adler@meggle.de

Resources

Click on MEGGLE launches DirectCost tool for more information
Click on MEGGLE to contact the company directly.
Click on DirectCost to get linked to the DEMO Version.
Click on DirectCost Manual to download a copy of the user manual.

DirectCost guides users step by step through typical tableting projects to quantify savings from switching from WG to DC process

DirectCost guides users step by step through typical tableting projects to quantify savings from switching from WG to DC process

M2

M3


Supplier Information
Supplier: MEGGLE Excipients & Technology
Address: Megglestrasse 6-12, 83512 Wasserburg, Germany
Tel: +49 8071 73-476
Fax: +49 8071 73-320
Website: https://www.meggle-pharma.com/


MEGGLE to feature in ‘virtual tour’ of CPhI China in Shanghai


MEGGLE to feature in ‘virtual tour’ of CPhI China in Shanghai


Meggle Logo

Press Release | MEGGLE Excipients & Technology

JUNE 06, 2017

Wasserburg, Germany: – Pharmaceutical lactose specialist MEGGLE Excipients &Technology (MEGGLE) will return as an exhibitor to the huge CPhI China expo in Shanghai to showcase its innovative range of lactose-based pharmaceutical agents and excipients to a fast-growing Asian market.

MEGGLE will be exhibiting in partnership with local partners Guangzhou Standard Pharma Ltd. and Shanghai Pintech Pharmaceutical Co., Ltd. at Booth W5B02 at the Shanghai’s huge SNIEC Exhibition Center.

Organisers UBM Live have selected the MEGGLE stand as one of the highlights of their featured ‘CPhI China New Exhibitors in Excipients Zone Discovery Tour’. This will also include a virtual reality dimension, with VR images of the stand posted to the CPhI website. This will allow a worldwide audience to ‘visit’ the MEGGLE display online.

Ground-breaking lactose excipients

The MEGGLE team led by Dr. Yi Kang, Dr. Xiaolong Chen, Fisher Yu, Raymond Huang and Sophia Yao from the Shanghai Representative Office will be showcasing the wide range of their lactose-based products and co-processed excipients including the ground-breaking Tablettose® and FlowLac® spray-dried alpha-lactose monohydrates, both of which have helped revolutionize direct compression tableting.

MEGGLE will also show Cellactose®, GranuLac® and the InhaLac® inhalation lactose, now strengthened by the addition of micronized InhaLac® 500.

Growing Asian markets

“We are delighted to be returning to Shanghai as an exhibitor and proud to have our display selected to feature as a stop on the New Exhibitors Tour of the Excipients Zone,” said Dr. Yi Kang.

“CPhI China has become a key exhibition for pharmaceutical companies in China and also worldwide and therefore provides a key platform to reach our growing Asian market,” said Dr. Yi.

Video screens on the stand will provide visitors with insights into MEGGLE’s rigorous production standards, advanced technology and pioneering research work.

About MEGGLE Wasserburg

Bavarian-based MEGGLE Wasserburg is one of the world’s foremost experts in lactose and its applications in pharmaceuticals.

From its roots as a dairy operation in the late 1880s, MEGGLE has become one of the world’s leading manufacturers of pharmaceutical lactose, supplying the pharma market segment with a broad-based and unique lactose product portfolio.

MEGGLE Excipients & Technology has harnessed outstanding product quality and intelligent innovation to become a global leader in the manufacture of lactose-based excipients, focusing on products for direct tableting and dry powder inhalation.

A multidisciplinary team of committed and highly qualified people allows MEGGLE clients to benefit from pioneering experience and innovative drive in industrial milk and whey processing. The company constantly strives to develop high-tech, functional products for implementation in customer applications, where they can deliver maximum performance.

The company has introduced several pioneering products, notably Tablettose®, the world’s first agglomerated lactose for direct tableting, Cellactose® 80, a pioneering co-processed excipient based on cellulose-lactose for outstanding compression and flow properties and RetaLac®, the first co-processed excipient to use a hypromellose-lactose base for extended release formulations.

In 2005, MEGGLE opened its FormulaB Centre of Excellence in Odessa, Ukraine, to develop pharmaceutical compounds and manufacture clinical trial materials.

About CPhI China 2017

Since Y2000, CPhI China has established itself as the leading pharma industry business and sourcing event for Eastern Asia, reflecting the huge growth of the Chinese pharma market.

Staged by global B2B events organizer and publisher, UBM Live, CPhI China is a three-day event opening June 20 at the Shanghai New International Exhibition Center (SNIEC).

CPhI China is co-located with five other pharma industry events, P-Mec for machinery and equipment, ICSE for outsourcing solutions BioPh for biotech solution, InnoPack for Drug Packaging and Delivery Technology and LABWorld for laboratory equipment. Together, the shows bring together more than 2,800 suppliers and are likely to attract some 40,000 visitors from more than 100 countries.

CPhI & P-MEC China also part of the wider China Pharma Week, spanning five working days from June 19 that features some 14 events focusing on Business, Knowledge, Leadership, Innovation, Recognition and Networking in the field of Pharma.

More information at http://www.cphi-china.cn/en

Media Contact

Margit Bonnetsmüller, Project Manager Marketing, MEGGLE Excipients &Technology Business Group
Tel: +49 8071 73 476
Email: Margit.Bonnetsmueller@meggle.de

Resources

Click on MEGGLE returns to CPhI China for more information
Click on MEGGLE to contact the company directly.

M1
m2m3


Supplier Information
Supplier: MEGGLE Excipients & Technology
Address: Megglestrasse 6-12, 83512 Wasserburg, Germany
Tel: +49 8071 73-476
Fax: +49 8071 73-320
Website: https://www.meggle-pharma.com/


MEGGLE launches micronized inhaler lactose InhaLac® 500


MEGGLE launches micronized inhaler lactose InhaLac® 500


Meggle Logo

Press Release | MEGGLE Excipients & Technology

MAY 10, 2017

Wasserburg, Germany: – Pharmaceutical lactose specialist MEGGLE Excipients & Technology (MEGGLE) has launched InhaLac® 500, its first micronized inhaler excipient.

Developed at MEGGLE’s Wasserburg laboratories in Germany, InhaLac® 500 is MEGGLE´s first micronized lactose grade, specifically designed for inhalation with extremely small particles. Combined with high quality and safety, this material meets the most demanding individual dry powder inhalation formulation requirements.

InhaLac® 500 is the finest grade of the InhaLac® product family which also includes sieved grades InhaLac® 70, InhaLac® 120, InhaLac® 230 and InhaLac® 251, along with milled grade InhaLac® 400.

High cohesion and stability

The micronization process used for InhaLac® 500 produces very small particles, high cohesive properties and even distribution, with 90 % of the particles being smaller than 10 μm (x50 ≤ 5 μm). This allows a wider choice of applications as fines or as co-agglomerate in dry powder inhalation products.

A further key benefit is long shelf life, with high stability and a retest date of 12 month.

Versatile applications

InhaLac® 500 is a micronized ultra fine lactose that is suitable for ternary DPI formulations. The addition of micronized fines improves the drug product performance, particularly with regard to fine particle fractions (FPF) when used in ternary mixtures. This can be related to several known effects, such as buffer effect or the saturation of high-energy active sites. Further, the high cohesiveness of the micronized material helps to alter the fluidization behavior of the powder blend.

The micronized size with an x90 smaller than 10 µm, makes InhaLac® 500 ideally suited for application in soft spherical pellet formulations and across a range of different formulation types, for example as micronized fines in ternary adhesive mixtures (5-15 % wt.) or as filler in soft spherical pellets.

About MEGGLE Wasserburg

MEGGLE AG, with its headquarters in the Bavarian city of Wasserburg, serves as a holding company for various business activities in the dairy industry and whey processing. MEGGLE has a proud history of more than 125 years in the dairy market.

The MEGGLE Excipients & Technology business group produces pharmaceutical excipients for direct compression, granulation, capsules, sachets, powder blends and dry powder inhalers. With its broad product portfolio, intelligent innovations and exceptional product quality, MEGGLE has assumed a leading role in the global business of pharmaceutical excipients as an acknowledged world expert in lactose and its applications in pharmaceuticals.

MEGGLE Excipients & Technology has harnessed outstanding product quality and intelligent innovation to become a global leader in the manufacture of lactose-based excipients, focusing on products for direct tableting and dry powder inhalation.

BG Excipients & Technology has introduced several pioneering products, notably Tablettose®, the world’s first agglomerated lactose for direct tableting, Cellactose® 80, a pioneering co-processed excipient based on cellulose-lactose for outstanding compression and flow properties and RetaLac®, the first co-processed excipient to use a hypromellose-lactose base for extended release formulations.

Media Contacts

Dr. Mirjam Kobler, MEGGLE Excipients & Technology
Tel: +49 8071 73 138
Email: Mirjam.kobler@meggle.de

OR

Ruth Leinenbach, Director MEGGLE BG Excipients & Technology
Tel: +49 8071 73 495
Email: service.pharma@meggle.de

Resources

Click on MEGGLE micronized inhaler lactose InhaLac® 500 for more information
Click on MEGGLE to contact the company directly.
Click on InhaLac 500 brochure for download.

 Typical cumulative PSD and distribution density of MEGGLE’s milled and micronized dry powder inhaler lactose grade InhaLac 400 and InhaLac 500. Analyzed by Sympatec/Helos & Rodos laser diffraction system.

Typical cumulative PSD and distribution density of MEGGLE’s milled and micronized dry powder inhaler lactose grade InhaLac 400 and InhaLac 500. Analyzed by Sympatec/Helos & Rodos laser diffraction system

 Typical cumulative PSD and distribution density of MEGGLE’s milled and micronized dry powder inhaler lactose grade InhaLac 400 and InhaLac 500. Analyzed by Sympatec/Helos & Rodos laser diffraction system.

Typical cumulative PSD and distribution density of MEGGLE’s milled and micronized dry powder inhaler lactose grade InhaLac 400 and InhaLac 500. Analyzed by Sympatec/Helos & Rodos laser diffraction system


Supplier Information
Supplier: MEGGLE Excipients & Technology
Address: Megglestrasse 6-12, 83512 Wasserburg, Germany
Tel: +49 8071 73-476
Fax: +49 8071 73-320
Website: https://www.meggle-pharma.com/


Dry Powder Inhaler – Sieved, Milled, Micronized Lactose: MEGGLE’s InhaLac®


Dry Powder Inhaler – Sieved, Milled, Micronized Lactose: MEGGLE’s InhaLac®


Meggle Logo

Products & Services | MEGGLE Excipients & Technology

APRIL 27, 2017

To learn more about Dry Powder Inhaler – Sieved, Milled, Micronized Lactose: MEGGLE’s InhaLac®, please click on the brochure below:

DOWNLOAD BROCURE

DOWNLOAD BROCURE

Resources

Click on Dry Powder Inhaler – Sieved, Milled, Micronized Lactose: MEGGLE’s InhaLac® for more information
Click on MEGGLE to contact the company directly.


Supplier Information
Supplier: MEGGLE Excipients & Technology
Address: Megglestrasse 6-12, 83512 Wasserburg, Germany
Tel: +49 8071 73-476
Fax: +49 8071 73-320
Website: https://www.meggle-pharma.com/